Doxorubicin hydrochloride (Synonyms: Hydroxydaunorubicin hydrochloride; ADR)

Name: Doxorubicin hydrochloride
Brand: MedChemExpress
SKU: HY-15142
Rating: 5.0 (441 reviews)

Cat. No.: HY-15142 Purity: 99.90%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.

For research use only. We do not sell to patients.

Doxorubicin hydrochloride Chemical Structure

CAS No. : 25316-40-9

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 66	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 66	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 84	In-stock	Estimated Time of Arrival: December 31
200 mg	USD 144	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 264	In-stock	Estimated Time of Arrival: December 31
1 g	USD 474	In-stock	Estimated Time of Arrival: December 31
5 g		Get quote
10 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 441 publication(s) in Google Scholar

Other Forms of Doxorubicin hydrochloride:

Doxorubicin-13C,d3 Get quote
Doxorubicin Get quote
Doxorubicin hydrochloride (Standard) Get quote

430 Publications Citing Use of MCE Doxorubicin hydrochloride

IHC

: Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887. [Abstract]; Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Western blotting analysis and quantification of KRT8 protein expression (normalized to GAPDH expression).

: Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887. [Abstract]; Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Representative images of immunofluorescence staining of KRT8 of CM318 and UCH1 cell line.

: Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2019 Jan;130:557-567. [Abstract]; Representative pictures of Live/Dead staining of effects of 7,8-DHF on high dose of Dox-induced cell death and MMP reduction of H9c2 cells.

: Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Sep;23(9):6034-6047. [Abstract]; Effects of YWPC (50 mg/L for 24 h) on DOX (5 μM for 24 h)-induces dissipation of mitochondrial membrane potential measured in H9C2 cells loaded with JC-1 using fluorescence microscopy.

: Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139. [Abstract]; One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.

: Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2018 Jan 2;128(1):483-499. [Abstract]; Immunoblotting for EZH2 in lysates of immortalized mouse podocytes after treatment with Adriamycin (300 ng/mL) for 48 hours (n=6).

: Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Sep 19;37(1):232. [Abstract]; Immunoblotting shows that both P-gp protein expression is significantly decreased in 24 h after US exposure in MCF-7/ADR and HEPG2/ADM cells.

: Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Nanoscale Res Lett. 2018 Nov 3;13(1):350. [Abstract]; HY-15142

: Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 May 1;36:108-116. [Abstract]; PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), CDDP (for 24 h) and Doxorubicin (for 10 h) as indicated, followed by immunoblotting with the antibodies.

: Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;42(3):965-973. [Abstract]; U937 cells are treated with Thapsigargin (TG, 1 μM), NSC 125973 (PTX, 5nM) as well as Doxorubincin (DOX, 1 μM) for 12 hours and the indicated proteins are detected by Western blot.

: Doxorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Med. 2016 May;22(5):547-56. [Abstract]; Immunofluorescent staining for α-actinin (ACTN2) and cardiac troponin T (TNNT2) to demonstrate sarcomeric organization in hiPSC–CMs derived from patients who do not experience Doxorubicin–induced cardiotoxicity (DOX) versus those who do experience Doxorubicin-induced cardiotoxicity (DOXTOX) after 24 h treatment with Doxorubicin. Scale bar, 20 µm.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II

View All ADC Cytotoxin Isoform Specific Products:

View All Isoforms

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

View All AMPK Isoform Specific Products:

View All Isoforms

NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2]^[3]

Topoisomerase I

0.8 μM (IC₅₀)

Topoisomerase II

2.67 μM (IC₅₀)

Daunorubicins/Doxorubicins

HIV-1

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	0.8 μM Compound: ADR	Antiproliferative activity against mouse 4T1 cells measured after 72 hrs by MTT assay Antiproliferative activity against mouse 4T1 cells measured after 72 hrs by MTT assay	[PMID: 30739826]
518A2	IC₅₀	0.12 μM Compound: 1	Cytotoxicity against human 518A2 cells after 72 hrs by MTT assay Cytotoxicity against human 518A2 cells after 72 hrs by MTT assay	[PMID: 20133021]
518A2	IC₅₀	0.17 μM Compound: 1	Cytotoxicity against human 518A2 cells after 48 hrs by MTT assay Cytotoxicity against human 518A2 cells after 48 hrs by MTT assay	[PMID: 20133021]
518A2	IC₅₀	0.34 μM Compound: 1	Cytotoxicity against human 518A2 cells after 24 hrs by MTT assay Cytotoxicity against human 518A2 cells after 24 hrs by MTT assay	[PMID: 20133021]
647-V	IC₅₀	< 0.068 mg/mL Compound: Doxorubicin	Cytotoxicity against human 647V cells after 24 hrs by MTT assay Cytotoxicity against human 647V cells after 24 hrs by MTT assay	[PMID: 22142614]
769-P	IC₅₀	11.5 μM Compound: Adriamycin	Cytotoxicity against human 769-P cells by MTT assay Cytotoxicity against human 769-P cells by MTT assay	[PMID: 21875764]
769-P	IC₅₀	11.5 μM Compound: Adriamycin	Cytotoxicity against human 769-P cells by MTT assay Cytotoxicity against human 769-P cells by MTT assay	[PMID: 20627721]
786-0	GI₅₀	0.43 μg/mL Compound: Doxorubicin	Cytotoxicity against human 786-0 cells assessed as growth inhibition by SRB assay Cytotoxicity against human 786-0 cells assessed as growth inhibition by SRB assay	[PMID: 24507920]
786-0	IC₅₀	3.1 μM Compound: Adriamycin	Cytotoxicity against human 786-0 cells by MTT assay Cytotoxicity against human 786-0 cells by MTT assay	[PMID: 21875764]
786-0	IC₅₀	3.1 μM Compound: Adriamycin	Cytotoxicity against human 786-0 cells by MTT assay Cytotoxicity against human 786-0 cells by MTT assay	[PMID: 20627721]
A 172	IC₅₀	18.5 μM Compound: Adriamycin	Cytotoxicity against human A172 cells by MTT assay Cytotoxicity against human A172 cells by MTT assay	[PMID: 25304898]
A2780	GI₅₀	< 0.1 μM Compound: ADR	Anticancer activity against human A2780 cells after 48 hrs by SRB assay Anticancer activity against human A2780 cells after 48 hrs by SRB assay	[PMID: 20557981]
A2780	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human A2780 cells after 48 hrs by SRB assay Cytotoxicity against human A2780 cells after 48 hrs by SRB assay	[PMID: 20554354]
A2780	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B based ELISA Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B based ELISA	[PMID: 21402478]
A2780	GI₅₀	0.16 μM Compound: ADR	Cytotoxicity against human A2780 cells after 48 hrs by SRB assay Cytotoxicity against human A2780 cells after 48 hrs by SRB assay	[PMID: 20444601]
A2780	GI₅₀	0.16 μM Compound: ADR	Cytotoxicity against human A2780 cells by sulforhodamine B method Cytotoxicity against human A2780 cells by sulforhodamine B method	[PMID: 21459581]
A2780	GI₅₀	0.18 μM Compound: ADR	Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 21194809]
A2780	IC₅₀	0.5 μM Compound: Adriamycin	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 30137985]
A2780	IC₅₀	2.03 μM Compound: ADM	Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
A2780	IC₅₀	2.69 μM Compound: ADM	Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
A-375	IC₅₀	0.73 μM Compound: Doxorubicin.HCl	Cytotoxicity against human A375 cells after 48 hrs by MTT assay Cytotoxicity against human A375 cells after 48 hrs by MTT assay	[PMID: 23131338]
A-375	IC₅₀	17.2 μM Compound: Adriamycin	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 21875764]
A-375	IC₅₀	17.2 μM Compound: Adriamycin	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 20627721]
A-427	IC₅₀	1.3 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human A-427 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A-427 cells assessed as reduction in cell viability by MTT assay	[PMID: 34176266]
A549	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 20554354]
A549	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B based ELISA Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B based ELISA	[PMID: 21402478]
A549	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31804070]
A549	IC₅₀	0.002 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as decrease in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability by MTT assay	[PMID: 29489361]
A549	EC₅₀	0.04 μM Compound: doxorubicin HCl	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 12027739]
A549	IC₅₀	0.04 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay	10.1039/C5MD00289C
A549	GI₅₀	0.06 μM Compound: doxorubicin hydrochloride	Antitumor activity against human A549 cells after 72 hrs by SRB assay Antitumor activity against human A549 cells after 72 hrs by SRB assay	[PMID: 21718029]
A549	IC₅₀	0.1 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 30049584]
A549	IC₅₀	0.1 μM Compound: ADM	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 28749671]
A549	IC₅₀	0.1 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 25259515]
A549	IC₅₀	0.12 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30222343]
A549	GI₅₀	0.13 μM Compound: ADR	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 21194809]
A549	IC₅₀	0.14 μM Compound: ADR	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30006167]
A549	IC₅₀	0.16 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 29407953]
A549	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as inhibition of cell growth by CCK-8 assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 36583957]
A549	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34282909]
A549	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 26506221]
A549	IC₅₀	0.2 μM Compound: adriamycin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23806071]
A549	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 24 hrs by SRB method Cytotoxicity against human A549 cells after 24 hrs by SRB method	[PMID: 31904949]
A549	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 24 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 24 hrs by sulforhodamine B assay	[PMID: 28418245]
A549	IC₅₀	0.29 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34165979]
A549	IC₅₀	0.3 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 27462726]
A549	IC₅₀	0.329 μM Compound: Doxorubicin HCl	Antiproliferative activity against Homo sapiens (human) A549 cells after 72 hr by SRB assay Antiproliferative activity against Homo sapiens (human) A549 cells after 72 hr by SRB assay	10.1007/s00044-012-0443-x
A549	IC₅₀	0.329 μM Compound: Doxorubicin HCl	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 22748378]
A549	IC₅₀	0.33 μM Compound: Doxorubicin HCl	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by SRB assay	[PMID: 24686018]
A549	IC₅₀	0.33 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 24686017]
A549	IC₅₀	0.33 μM Compound: DOX	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 22574992]
A549	IC₅₀	0.4 μM Compound: Adriamycin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 35121401]
A549	IC₅₀	0.4 μM Compound: Adriamycin	Cytotoxicity against human A549 cells measured after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells measured after 72 hrs by CCK8 assay	[PMID: 31117522]
A549	IC₅₀	0.41 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay	[PMID: 21192108]
A549	IC₅₀	0.44 μM Compound: Adr	Cytotoxicity in human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay Cytotoxicity in human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 31184894]
A549	IC₅₀	0.481 μM Compound: Adr	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 29182349]
A549	IC₅₀	0.5 μM Compound: DOX.HCl	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28445049]
A549	IC₅₀	0.54 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21123066]
A549	IC₅₀	0.69 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34081476]
A549	IC₅₀	0.7 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 32293887]
A549	IC₅₀	0.78 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 33689875]
A549	IC₅₀	0.85 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as cell growth inhibition by SRB assay Cytotoxicity against human A549 cells assessed as cell growth inhibition by SRB assay	[PMID: 34762434]
A549	IC₅₀	0.9 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 34176266]
A549	IC₅₀	1.03 μM Compound: ADM	Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
A549	IC₅₀	1.13 μM Compound: ADR	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
A549	IC₅₀	1.2 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34797067]
A549	IC₅₀	1.2 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as cell viability inhibition for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability inhibition for 48 hrs by MTT assay	[PMID: 33913326]
A549	IC₅₀	1.3 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30137985]
A549	IC₅₀	1.3 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 29286660]
A549	IC₅₀	1.45 μM Compound: ADR	Antiproliferative activity in human A549 cells after 48 hrs by MTT assay Antiproliferative activity in human A549 cells after 48 hrs by MTT assay	[PMID: 28570977]
A549	IC₅₀	1.65 μM Compound: ADR	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30677614]
A549	IC₅₀	1.7 μM Compound: ADR	Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 33097300]
A549	IC₅₀	1.8 μM Compound: Adriamycin	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31268321]
A549	IC₅₀	12.5 μM Compound: ADM	Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
A549	IC₅₀	152 nM Compound: Adriamycin	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of (R)-4-((3,4-dibenzyl-2,5-dioxopiperazin-1-yl)methyl)-N-hydroxybenzamide by alamar blue assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of (R)-4-((3,4-dibenzyl-2,5-dioxopiperazin-1-yl)methyl)-N-hydroxybenzamide by alamar blue assay	[PMID: 31865013]
A549	IC₅₀	2.19 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay	[PMID: 34237623]
A549	IC₅₀	2.3 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33301677]
A549	IC₅₀	2.36 μM Compound: Adriamycin	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32485531]
A549	IC₅₀	2.8 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23477504]
A549	IC₅₀	2.9 μM Compound: Adriamycin	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31117521]
A549	IC₅₀	2.9 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 27704808]
A549	IC₅₀	23.71 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 25226363]
A549	IC₅₀	255 nM Compound: Adriamycin	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay	[PMID: 31865013]
A549	IC₅₀	4.3 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25304898]
A549	IC₅₀	5 μM Compound: Adriamycin	Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 32394716]
A549	GI₅₀	60.3 nM Compound: Doxorubicin HCl	Growth inhibition of human A549 cells after 72 hrs by SRB assay Growth inhibition of human A549 cells after 72 hrs by SRB assay	[PMID: 22607205]
A549	GI₅₀	7.25 mM Compound: Adriamycin	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 32631569]
A549	GI₅₀	7.25 μM Compound: ADR	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 20444601]
A549	GI₅₀	7.25 μM Compound: ADR	Cytotoxicity against human A549 cells by sulforhodamine B method Cytotoxicity against human A549 cells by sulforhodamine B method	[PMID: 21459581]
A549	IC₅₀	8.5 μM Compound: Doxorubicin HCl	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29884536]
A549/TR	IC₅₀	42.57 μM Compound: ADR	Cytotoxicity against human A549/TAX cells after 72 hrs by MTT assay Cytotoxicity against human A549/TAX cells after 72 hrs by MTT assay	[PMID: 30677614]
ACHN	GI₅₀	0.07 μM Compound: Adriamycin	Growth inhibition of human ACHN cells by SRB assay Growth inhibition of human ACHN cells by SRB assay	[PMID: 36040099]
ACHN	GI₅₀	0.07 μM Compound: Adriamycin	Cytotoxicity against human ACHN cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay Cytotoxicity against human ACHN cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay	[PMID: 29878761]
ACHN	GI₅₀	0.13 μM Compound: ADR	Cytotoxicity against human ACHN cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human ACHN cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 31668073]
ACHN	IC₅₀	0.17 μM Compound: ADR	Cytotoxicity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB method Cytotoxicity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB method	[PMID: 35302779]
ACHN	IC₅₀	0.26 μM Compound: Adriamycin	Anti-proliferative activity against human ACHN cells by XTT assay Anti-proliferative activity against human ACHN cells by XTT assay	[PMID: 25442319]
AG1523	IC₅₀	0.4 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human AG01523 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human AG01523 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33774342]
ASPC1	IC₅₀	< 5 μM Compound: Adriamycin	Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
ASPC1	IC₅₀	0.2 μM Compound: ADM	Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay	[PMID: 35993848]
ASPC1	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay	[PMID: 32840364]
ASPC1	IC₅₀	0.3 μM Compound: ADM	Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35380848]
ASPC1	IC₅₀	1.6 μM Compound: Adriamycin	Cytotoxicity against human Aspc-1 cells after 72 hrs under normoxic condition by MTT assay Cytotoxicity against human Aspc-1 cells after 72 hrs under normoxic condition by MTT assay	[PMID: 29656202]
ASPC1	IC₅₀	2 μM Compound: Adriamycin	Cytotoxicity against human Aspc-1 cells after 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human Aspc-1 cells after 72 hrs under hypoxic condition by MTT assay	[PMID: 29656202]
B16	IC₅₀	6.4 μM Compound: Adriamycin	Growth inhibition of mouse B16 cells by MTT method Growth inhibition of mouse B16 cells by MTT method	[PMID: 25611131]
B16-BL6	EC₅₀	0.11 μM Compound: doxorubicin HCl	Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 12027739]
B16-BL6	IC₅₀	0.2 μM Compound: Doxorubicin HCl	Antiproliferative activity against mouse B16-BL6 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against mouse B16-BL6 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 11575942]
B16-F10	GI₅₀	0.22 μg/mL Compound: Doxorubicin	Cytotoxicity against mouse B16F10 cells assessed as growth inhibition by SRB assay Cytotoxicity against mouse B16F10 cells assessed as growth inhibition by SRB assay	[PMID: 24507920]
BALB/3T3	IC₅₀	1.078 μM Compound: Doxorubicin HCl	Cytotoxicity against Mus musculus (mouse) BALB/3T3 cells after 72 hr by SRB assay Cytotoxicity against Mus musculus (mouse) BALB/3T3 cells after 72 hr by SRB assay	10.1007/s00044-012-0443-x
BALB/3T3	IC₅₀	1.078 μM Compound: Doxorubicin HCl	Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs by SRB assay Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs by SRB assay	[PMID: 22748378]
BALB/3T3	IC₅₀	1.08 μM Compound: Doxorubicin HCl	Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 72 hrs by SRB assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 72 hrs by SRB assay	[PMID: 24686018]
BALB/3T3	IC₅₀	1.08 μM Compound: DOX	Cytotoxicity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 24686017]
Bcap37	IC₅₀	0.94 μM Compound: ADM	Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay	[PMID: 25064351]
Bel-7402	IC₅₀	0.274 μM Compound: ADR	Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33676300]
Bel-7402	IC₅₀	0.274 μM Compound: ADR	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 30530194]
Bel-7402	IC₅₀	0.3 μM Compound: Adriamycin	Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability by SRB assay	[PMID: 32840364]
Bel-7402	IC₅₀	0.369 nM Compound: Adriamycin	Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35152092]
Bel-7402	IC₅₀	0.4 μM Compound: Adriamycin	Cytotoxicity against human Bel7402 cells after 24 hrs by SRB method Cytotoxicity against human Bel7402 cells after 24 hrs by SRB method	[PMID: 31904949]
Bel-7402	IC₅₀	0.73 μM Compound: ADR	Antiproliferative activity against human Bel7402 incubated for 72 hrs by MTT assay Antiproliferative activity against human Bel7402 incubated for 72 hrs by MTT assay	[PMID: 31553932]
Bel-7402	IC₅₀	0.73 μM Compound: ADR	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 30006167]
Bel-7402	IC₅₀	0.83 μM Compound: Adriamycin	Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27158140]
Bel-7402	IC₅₀	1.732 μM Compound: ADR	Antiproliferative activity against ADR-resistant human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against ADR-resistant human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33676300]
Bel-7402	IC₅₀	11.7 μM Compound: Adriamycin	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 25304898]
Bel-7402	IC₅₀	128 μM Compound: Adriamycin	Cytotoxicity against human Bel-7402 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay Cytotoxicity against human Bel-7402 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay	[PMID: 34237623]
Bel7402/5-FU	IC₅₀	10.95 μM Compound: ADR	Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay	[PMID: 30677614]
Bel7402/5-FU	IC₅₀	8.36 μM Compound: ADR	Antiproliferative activity against human Bel7402/5-FU incubated for 72 hrs by MTT assay Antiproliferative activity against human Bel7402/5-FU incubated for 72 hrs by MTT assay	[PMID: 31553932]
BGC-823	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
BGC-823	IC₅₀	< 1.3 μM Compound: Adriamycin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 21875764]
BGC-823	IC₅₀	0.01 μM Compound: Doxorubicin.HCl	Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay	[PMID: 23131338]
BGC-823	IC₅₀	0.76 μM Compound: adriamycin	Cytotoxic activity against human BGC823 cells by MTT method Cytotoxic activity against human BGC823 cells by MTT method	[PMID: 25739048]
BGC-823	IC₅₀	1.33 μM Compound: Adriamycin	Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay	[PMID: 21123066]
BGC-823	IC₅₀	1.48 μM Compound: Adriamycin	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human BGC823 cells assessed as reduction in cell viability by MTT assay	[PMID: 26933756]
BGC-823	IC₅₀	1.5 μM Compound: Adriamycin	Cytotoxicity against human BGC823 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay Cytotoxicity against human BGC823 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay	[PMID: 28206772]
BT-474	IC₅₀	3.2 μM Compound: Adriamycin	Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay	[PMID: 26988802]
C6	IC₅₀	0.06 μM Compound: ADR	Antiproliferative activity against rat C6 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against rat C6 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31977207]
Caco-2	IC₅₀	0.97 μM Compound: Adriamycin	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability by MTT assay	[PMID: 26933756]
CCRF-CEM	IC₅₀	0.15 μM Compound: Dox	Cytotoxicity against human CCRF-CEM cells after 48 hrs by Alamar blue assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by Alamar blue assay	[PMID: 25064348]
COLO 205	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B based ELISA Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B based ELISA	[PMID: 21402478]
COLO 205	GI₅₀	0.13 μM Compound: ADR	Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay	[PMID: 20554354]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay	[PMID: 20444601]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human COLO205 cells by sulforhodamine B method Cytotoxicity against human COLO205 cells by sulforhodamine B method	[PMID: 21459581]
CWR22R	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human 22Rv1 cells by MTT assay Cytotoxicity against human 22Rv1 cells by MTT assay	[PMID: 20627721]
CWR22R	IC₅₀	< 1.3 μM Compound: Adriamycin	Cytotoxicity against human 22Rv1 cells by MTT assay Cytotoxicity against human 22Rv1 cells by MTT assay	[PMID: 21875764]
DU-145	IC₅₀	0.21 μM Compound: Doxorubicin.HCl	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
DU-145	IC₅₀	0.52 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay	[PMID: 26945111]
DU-145	IC₅₀	0.52 μM Compound: Adriamycin	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
DU-145	IC₅₀	0.87 μM Compound: Adriamycin	Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
DU-145	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
DU-145	IC₅₀	1.02 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
DU-145	IC₅₀	1.19 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 20093033]
DU-145	IC₅₀	1.3 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 3 days Cytotoxicity against human DU145 cells after 3 days	[PMID: 19954977]
DU-145	IC₅₀	1.4 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 4 days by MTT assay Cytotoxicity against human DU145 cells after 4 days by MTT assay	[PMID: 20619511]
DU-145	IC₅₀	1.5 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay	[PMID: 19939682]
DU-145	IC₅₀	1.59 μM Compound: Adriamycin	Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
DU-145	IC₅₀	2.47 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 21419530]
DU-145	IC₅₀	2.54 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 19836231]
DU-145	IC₅₀	2.99 μM Compound: Adriamycin	Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
DU-145	IC₅₀	21.45 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 24 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 hrs by MTT assay	[PMID: 25226363]
DU-145	IC₅₀	3.89 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay	[PMID: 25062006]
DU-145	IC₅₀	4.88 μM Compound: ADM	Cytotoxicity against human DU145 cells after 72 hrs by cell counting kit-8 analysis Cytotoxicity against human DU145 cells after 72 hrs by cell counting kit-8 analysis	[PMID: 29174815]
ECa-109 cell line	IC₅₀	0.201 nM Compound: Adriamycin	Cytotoxicity against human Eca-109 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human Eca-109 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35152092]
H69AR	IC₅₀	15.1 μM Compound: ADM	Cytotoxicity against human H69AR cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human H69AR cells assessed as reduction in cell viability by SRB assay	[PMID: 35993848]
HBL-100	IC₅₀	0.14 mg/mL Compound: Doxorubicin	Cytotoxicity against human HBL100 cells after 24 hrs by MTT assay Cytotoxicity against human HBL100 cells after 24 hrs by MTT assay	[PMID: 22142614]
HCC70	IC₅₀	1.45 μM Compound: Adriamycin	Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay	[PMID: 31398033]
HCT-116	IC₅₀	> 1.25 μM Compound: Adriamycin	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
HCT-116	IC₅₀	0.0012 μM Compound: Adiramycin	Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 33940466]
HCT-116	IC₅₀	0.01 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay	10.1039/C5MD00289C
HCT-116	IC₅₀	0.06 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by SRB assay	[PMID: 31436991]
HCT-116	IC₅₀	0.1 μM Compound: ADR	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 35762988]
HCT-116	IC₅₀	0.1 μM Compound: Adriamycin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay	[PMID: 32840364]
HCT-116	IC₅₀	0.16 μM Compound: Adriamycin	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34165979]
HCT-116	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34282909]
HCT-116	IC₅₀	0.2 μM Compound: ADM	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29985604]
HCT-116	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26506221]
HCT-116	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells after 24 hrs by SRB method Cytotoxicity against human HCT116 cells after 24 hrs by SRB method	[PMID: 31904949]
HCT-116	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32880456]
HCT-116	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells after 24 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 24 hrs by sulforhodamine B assay	[PMID: 28418245]
HCT-116	IC₅₀	0.39 μM Compound: Doxorubicin HCl	Antiproliferative activity against Homo sapiens (human) HCT116 cells after 72 hr by SRB assay Antiproliferative activity against Homo sapiens (human) HCT116 cells after 72 hr by SRB assay	10.1007/s00044-012-0443-x
HCT-116	IC₅₀	0.39 μM Compound: Doxorubicin HCl	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by SRB assay	[PMID: 24686018]
HCT-116	IC₅₀	0.39 μM Compound: Doxorubicin HCl	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 22748378]
HCT-116	IC₅₀	0.41 μM Compound: ADR	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30006167]
HCT-116	IC₅₀	0.41 μM Compound: adriamycin	Cytotoxic activity against human HCT116 cells by MTT method Cytotoxic activity against human HCT116 cells by MTT method	[PMID: 25739048]
HCT-116	IC₅₀	1.1 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells after 3 days Cytotoxicity against human HCT116 cells after 3 days	[PMID: 19954977]
HCT-116	IC₅₀	1.4 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay	[PMID: 28206772]
HCT-116	IC₅₀	2.31 μM Compound: ADM	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29232583]
HCT-116	IC₅₀	2.9 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay	[PMID: 34176266]
HCT-116	IC₅₀	3.03 μM Compound: Dox	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22318158]
HCT-116	IC₅₀	4 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells after 4 days by MTT assay Cytotoxicity against human HCT116 cells after 4 days by MTT assay	[PMID: 20619511]
HCT-116	IC₅₀	5 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318975]
HCT-116	IC₅₀	5 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26810315]
HCT-116	IC₅₀	6.81 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells after 2 days Cytotoxicity against human HCT116 cells after 2 days	[PMID: 21419530]
HCT-15	GI₅₀	0.05 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT15 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay	[PMID: 29878761]
HCT-15	IC₅₀	0.09 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay	[PMID: 26927425]
HCT-15	GI₅₀	0.09 μM Compound: Adriamycin	Growth inhibition of human HCT-15 cells by SRB assay Growth inhibition of human HCT-15 cells by SRB assay	[PMID: 36040099]
HCT-15	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 31668073]
HCT-15	IC₅₀	0.17 μM Compound: ADR	Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method	[PMID: 35302779]
HCT-15	IC₅₀	0.43 μM Compound: Adriamycin	Anti-proliferative activity against human HCT15 cells by XTT assay Anti-proliferative activity against human HCT15 cells by XTT assay	[PMID: 25442319]
HCT-15	IC₅₀	0.47 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
HCT-15	IC₅₀	0.51 μM Compound: Adriamycin	Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay	[PMID: 29402741]
HCT-15	IC₅₀	0.51 μM Compound: Adriamycin	Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay	[PMID: 30262132]
HCT-15	IC₅₀	0.73 μM Compound: Adriamycin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay	[PMID: 29510948]
HCT-15	IC₅₀	0.74 μM Compound: Adriamycin	Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
HCT-15	IC₅₀	0.74 μM Compound: Adriamycin	Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
HCT-15	IC₅₀	0.94 μM Compound: Adriamycin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 28633898]
HCT-15	IC₅₀	1 μM Compound: Adriamycin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 28068603]
HCT-15	IC₅₀	1.08 μM Compound: Adriamycin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HCT-15	IC₅₀	1.2 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
HCT-15	IC₅₀	1.21 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
HCT-15	IC₅₀	1.23 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay	[PMID: 26945111]
HCT-15	IC₅₀	1.28 μM Compound: Adriamycin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 28384547]
HCT-15	IC₅₀	1.89 μM Compound: Adriamycin	Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability after 48 hrs by by Ez-cytoX based microplate reader method Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability after 48 hrs by by Ez-cytoX based microplate reader method	[PMID: 34597897]
HCT-15	IC₅₀	136 μM Compound: Adriamycin	Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
HCT-15	IC₅₀	2.12 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay	[PMID: 19939682]
HCT-15	IC₅₀	2.59 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay	[PMID: 25062006]
HCT-15	IC₅₀	23 μM Compound: Adriamycin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 26988802]
HCT-15	IC₅₀	3.76 μM Compound: ADM	Cytotoxicity against human HCT15 cells after 72 hrs by cell counting kit-8 analysis Cytotoxicity against human HCT15 cells after 72 hrs by cell counting kit-8 analysis	[PMID: 29174815]
HCT-8	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
HCT-8	IC₅₀	21.6 μM Compound: ADM	Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
HCT-8	IC₅₀	3.98 μM Compound: ADM	Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 35282680]
HEK293	IC₅₀	0.37 μM Compound: ADM	Cytotoxicity against human HEK293 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30827866]
HEK293	IC₅₀	1.22 μM Compound: Adriamycin	Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay	[PMID: 25062006]
HEK293	IC₅₀	4.96 μM Compound: Adriamycin	Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HeLa	IC₅₀	< 0.068 mg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 22142614]
HeLa	GI₅₀	< 0.1 μM Compound: ADR	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 28188067]
HeLa	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27987486]
HeLa	IC₅₀	< 0.1 μM Compound: Adiramycin	Cytotoxicity against human HeLa cells by SRB method Cytotoxicity against human HeLa cells by SRB method	[PMID: 24951333]
HeLa	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
HeLa	IC₅₀	< 10 μM Compound: Adriamycin	Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 35694689]
HeLa	EC₅₀	0.02 μM Compound: doxorubicin HCl	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 12027739]
HeLa	IC₅₀	0.1 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells assessed as decrease in cell viability by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability by MTT assay	[PMID: 29489361]
HeLa	GI₅₀	0.17 μM Compound: DOX HCl	Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy	[PMID: 23353738]
HeLa	IC₅₀	0.18 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34165979]
HeLa	IC₅₀	0.3 μM Compound: ADM	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28749671]
HeLa	IC₅₀	0.31 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34081476]
HeLa	IC₅₀	0.31 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30222343]
HeLa	IC₅₀	0.43 μM Compound: ADM	Cytotoxicity against human HeLa cells after 2 days by MTT assay Cytotoxicity against human HeLa cells after 2 days by MTT assay	[PMID: 21821321]
HeLa	IC₅₀	0.48 μM Compound: Adriamycin	Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32485531]
HeLa	IC₅₀	0.5 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 32293887]
HeLa	IC₅₀	0.5 μM Compound: Adriamycin	Growth inhibition of human HeLa cells after 72 hrs by MTT assay Growth inhibition of human HeLa cells after 72 hrs by MTT assay	[PMID: 26539973]
HeLa	IC₅₀	0.5 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by SRB assay	[PMID: 27992183]
HeLa	IC₅₀	0.6 μM Compound: adriamycin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 23806071]
HeLa	IC₅₀	0.6 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 24 hrs by SRB method Cytotoxicity against human HeLa cells after 24 hrs by SRB method	[PMID: 31904949]
HeLa	IC₅₀	0.6 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 32880456]
HeLa	IC₅₀	0.6 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells by SRB assay Cytotoxicity against human HeLa cells by SRB assay	[PMID: 29407953]
HeLa	IC₅₀	0.6 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 24 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells after 24 hrs by sulforhodamine B assay	[PMID: 28418245]
HeLa	IC₅₀	0.602 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35152092]
HeLa	IC₅₀	0.69 μg/mL Compound: Dox	Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by MTT assay	10.1007/s00044-013-0486-7
HeLa	IC₅₀	0.71 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20093033]
HeLa	IC₅₀	0.72 μM Compound: adriamycin	Cytotoxic activity against human HeLa cells by MTT method Cytotoxic activity against human HeLa cells by MTT method	[PMID: 25739048]
HeLa	IC₅₀	0.8 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
HeLa	IC₅₀	0.81 μg/mL Compound: Dox	Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by SRB assay Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by SRB assay	10.1007/s00044-013-0486-7
HeLa	IC₅₀	0.82 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 3 days by CCK8 assay Cytotoxicity against human HeLa cells after 3 days by CCK8 assay	[PMID: 26927425]
HeLa	IC₅₀	0.88 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay	[PMID: 26945111]
HeLa	IC₅₀	0.88 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HeLa	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells assessed as inhibition of growth incubated for 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of growth incubated for 72 hrs by MTT assay	[PMID: 28206772]
HeLa	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
HeLa	IC₅₀	1.01 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
HeLa	IC₅₀	1.03 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Ez-cytoX based microplate reader method Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Ez-cytoX based microplate reader method	[PMID: 34597897]
HeLa	IC₅₀	1.06 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318123]
HeLa	IC₅₀	1.08 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19836231]
HeLa	IC₅₀	1.13 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay	[PMID: 19939682]
HeLa	IC₅₀	1.2 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 28384547]
HeLa	IC₅₀	1.2 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 28068603]
HeLa	IC₅₀	1.23 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28222318]
HeLa	IC₅₀	1.3 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 34176266]
HeLa	IC₅₀	1.32 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 2 days Cytotoxicity against human HeLa cells after 2 days	[PMID: 21419530]
HeLa	IC₅₀	1.35 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21123066]
HeLa	IC₅₀	1.36 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
HeLa	IC₅₀	1.4 μM Compound: Doxorubicin HCl	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29884536]
HeLa	IC₅₀	1.5 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay	[PMID: 29402741]
HeLa	IC₅₀	1.5 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay	[PMID: 30262132]
HeLa	IC₅₀	1.6 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 3 days Cytotoxicity against human HeLa cells after 3 days	[PMID: 19954977]
HeLa	IC₅₀	1.7 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay	[PMID: 29510948]
HeLa	IC₅₀	1.7 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
HeLa	IC₅₀	10.1 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 4 days by MTT assay Cytotoxicity against human HeLa cells after 4 days by MTT assay	[PMID: 20619511]
HeLa	IC₅₀	2.5 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318975]
HeLa	IC₅₀	2.77 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 28633898]
HeLa	IC₅₀	231 nM Compound: adriamycin	Cytotoxicity against wild type human HeLa cells by MTT assay Cytotoxicity against wild type human HeLa cells by MTT assay	[PMID: 16562842]
HeLa	IC₅₀	25.65 μM Compound: adriamycin	Cytotoxicity against MDR1-G185 overexpressing human HeLa cells by MTT assay Cytotoxicity against MDR1-G185 overexpressing human HeLa cells by MTT assay	[PMID: 16562842]
HeLa/Fucci2	IC₅₀	2 μM Compound: Adriamycin	Antiproliferative activity against human HeLa/Fucci2 cells assessed as inhibition of cell viability incubated for 3 days by MTT assay Antiproliferative activity against human HeLa/Fucci2 cells assessed as inhibition of cell viability incubated for 3 days by MTT assay	[PMID: 31848114]
HEp-2	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
HepG2	IC₅₀	< 0.068 mg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 22142614]
HepG2	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay	10.1007/s00044-012-0423-1
HepG2	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
HepG2	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31804070]
HepG2	IC₅₀	< 1.3 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21875764]
HepG2	IC₅₀	0.001 μM Compound: Adiramycin	Anticancer activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 33940466]
HepG2	IC₅₀	0.036 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells by SRB assay Cytotoxicity against human HepG2 cells by SRB assay	[PMID: 29407953]
HepG2	GI₅₀	0.04 μg/mL Compound: Adriamycin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27598688]
HepG2	IC₅₀	0.1 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability by MTT assay	[PMID: 29489361]
HepG2	IC₅₀	0.24 μM Compound: adriamycin	Cytotoxic activity against human HepG2 cells by MTT method Cytotoxic activity against human HepG2 cells by MTT method	[PMID: 25739048]
HepG2	IC₅₀	0.3 μM Compound: DOX.HCl	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28445049]
HepG2	IC₅₀	0.38 μM Compound: Adriamycin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 35121401]
HepG2	IC₅₀	0.4 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 34176266]
HepG2	IC₅₀	0.45 nM Compound: Adriamycin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35152092]
HepG2	IC₅₀	0.66 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 33689875]
HepG2	IC₅₀	0.67 μM Compound: ADM	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 28818459]
HepG2	IC₅₀	0.8 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34081476]
HepG2	IC₅₀	0.85 μM Compound: ADR	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
HepG2	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 20627721]
HepG2	IC₅₀	1.09 μM Compound: Dox	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22318158]
HepG2	IC₅₀	1.11 μM Compound: Doxorubicin.HCl	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23131338]
HepG2	IC₅₀	1.2 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 32293887]
HepG2	IC₅₀	1.5 μM Compound: Adriamycin	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31268321]
HepG2	IC₅₀	1.6 μM Compound: ADR	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 33097300]
HepG2	IC₅₀	1.9 μM Compound: Adriamycin	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31117521]
HepG2	IC₅₀	10.1 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 25304898]
HepG2	CC₅₀	127 μM Compound: ADR	Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 26675440]
HepG2	IC₅₀	2.08 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21144747]
HepG2	IC₅₀	2.21 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay	[PMID: 34237623]
HepG2	IC₅₀	2.32 μM Compound: ADM	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30739827]
HepG2	IC₅₀	2.5 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26810315]
HepG2	IC₅₀	2.6 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
HepG2/Adm	IC₅₀	144.35 μM Compound: ADM	Cytotoxicity against human HepG2/ADM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2/ADM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 28818459]
HFL1	IC₅₀	2.31 μM Compound: Adriamycin	Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HL-60	IC₅₀	0.01 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 15387667]
HL-60	IC₅₀	0.016 μM Compound: ADR	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 26832219]
HL-60	IC₅₀	0.019 μM Compound: Adriamycin	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by CCK-8 assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 36583957]
HL-60	IC₅₀	0.019 μM Compound: ADR	Cytotoxicity against human HL60 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay	[PMID: 28068601]
HL-60	IC₅₀	0.02 μM Compound: Adriamycin	Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 34762434]
HL-60	IC₅₀	0.02 μM Compound: Adriamycin	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32880456]
HL-60	IC₅₀	0.02 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 31904949]
HL-60	IC₅₀	0.02 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 29286660]
HL-60	IC₅₀	0.02 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 28418245]
HL-60	IC₅₀	0.02 μM Compound: Dox	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 26506221]
HL-60	GI₅₀	0.02 μM Compound: Doxorubicin hydrochloride	Growth inhibition of human HL60 cells measured after 3 days by trypan blue assay Growth inhibition of human HL60 cells measured after 3 days by trypan blue assay	[PMID: 29565129]
HL-60	IC₅₀	0.04 μM Compound: Adriamycin	Cytotoxicity against Homo sapiens (human) HL60 cells assessed as reduction in cell survival fraction after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HL60 cells assessed as reduction in cell survival fraction after 48 hr by MTT assay	10.1007/s00044-011-9703-4
HL-60	IC₅₀	0.067 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 27462726]
HL-60	IC₅₀	0.075 μM Compound: Adr	Cytotoxicity in human HL60 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay Cytotoxicity in human HL60 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 31184894]
HL-60	IC₅₀	0.076 μM Compound: Adr	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 29182349]
HL-60	IC₅₀	0.08 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells measured after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells measured after 72 hrs by CCK8 assay	[PMID: 31117522]
HL-60	IC₅₀	0.08 μM Compound: 1	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20133021]
HL-60	IC₅₀	0.1 μM Compound: adriamicin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 21090801]
HL-60	IC₅₀	0.1 μM Compound: 1	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20133021]
HL-60	IC₅₀	0.13 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 21192108]
HL-60	IC₅₀	0.14 μM Compound: ADM	Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30827866]
HL-60	IC₅₀	0.18 μM Compound: adriamycin	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19962306]
HL-60	IC₅₀	0.2 μM Compound: ADM	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 29985604]
HL-60	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay	[PMID: 32840364]
HL-60	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay	[PMID: 27992183]
HL-60	IC₅₀	0.22 μM Compound: 1	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 20133021]
HL-60	IC₅₀	0.32 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells after 2 days Cytotoxicity against human HL60 cells after 2 days	[PMID: 21419530]
HL-60	IC₅₀	0.7 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
HL-60	IC₅₀	0.88 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19836231]
HL-60	IC₅₀	0.94 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20093033]
HL60/ADR	IC₅₀	4.3 μM Compound: Adriamycin	Cytotoxicity against Homo sapiens (human) HL60/ADR cells assessed as reduction in cell survival fraction after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HL60/ADR cells assessed as reduction in cell survival fraction after 48 hr by MTT assay	10.1007/s00044-011-9703-4
HL60/ADR	IC₅₀	4.89 μM Compound: ADR	Cytotoxicity against human HL60/ADR cells after 72 hrs by MTT assay Cytotoxicity against human HL60/ADR cells after 72 hrs by MTT assay	[PMID: 26832219]
HOP-62	GI₅₀	0.12 μM Compound: ADR	Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay	[PMID: 20554354]
HOP-62	GI₅₀	0.14 mM Compound: Adriamycin	Growth inhibition of human HOP62 cells after 48 hrs by MTT assay Growth inhibition of human HOP62 cells after 48 hrs by MTT assay	[PMID: 32631569]
HOP-62	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay	[PMID: 20444601]
HOP-62	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human HOP62 cells by sulforhodamine B method Cytotoxicity against human HOP62 cells by sulforhodamine B method	[PMID: 21459581]
HT-1080	IC₅₀	0.008 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33774342]
HT-1080	IC₅₀	0.012 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 15387667]
HT-1080	EC₅₀	0.02 μM Compound: doxorubicin HCl	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 12027739]
HT-1080	ED₅₀	0.034 μg/mL Compound: doxorubicin HCl	Cytotoxicity against human HT1080 cells after 24 hrs by MTT assay Cytotoxicity against human HT1080 cells after 24 hrs by MTT assay	[PMID: 9677271]
HT-1080	IC₅₀	0.2 μM Compound: Doxorubicin HCl	Antiproliferative activity against human HT1080 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 11575942]
HT-1080	IC₅₀	0.38 μM Compound: Adriamycin	Cytotoxicity against human HT1080 cells assessed as reduction cell viability after 72 hrs by WST8-based colorimetric analysis Cytotoxicity against human HT1080 cells assessed as reduction cell viability after 72 hrs by WST8-based colorimetric analysis	[PMID: 27332142]
HT-29	GI₅₀	0.15 μM Compound: doxorubicin hydrochloride	Antitumor activity against human HT-29 cells after 72 hrs by SRB assay Antitumor activity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 21718029]
HT-29	GI₅₀	0.15 μM Compound: DOX HCl	Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
HT-29	IC₅₀	0.559 μM Compound: Adr	Cytotoxicity against human HT-29 cells by SRB assay Cytotoxicity against human HT-29 cells by SRB assay	[PMID: 29182349]
HT-29	IC₅₀	0.58 mg/mL Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay	[PMID: 22142614]
HT-29	IC₅₀	0.95 μM Compound: Adriamycin	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20093033]
HT-29	IC₅₀	1.46 μM Compound: Adriamycin	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318123]
HT-29	IC₅₀	1.76 μM Compound: Adriamycin	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 28222318]
HT-29	IC₅₀	1.8 μM Compound: Adriamycin	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33301677]
HT-29	GI₅₀	153 nM Compound: Doxorubicin HCl	Growth inhibition of human HT-29 cells after 72 hrs by SRB assay Growth inhibition of human HT-29 cells after 72 hrs by SRB assay	[PMID: 22607205]
HT-29	IC₅₀	2.6 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay	[PMID: 34176266]
HT-29	IC₅₀	3.8 μM Compound: Adriamycin	Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31268321]
HT-29	IC₅₀	3.8 μM Compound: Adriamycin	Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31117521]
HT-29	IC₅₀	3.9 μM Compound: Adriamycin	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 19836231]
HT-29	IC₅₀	4.2 μM Compound: Adriamycin	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 21875764]
HT-29	IC₅₀	4.2 μM Compound: Adriamycin	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 20627721]
Huh-7	IC₅₀	14.8 μM Compound: Adriamycin	Cytotoxicity against human HuH7 cells by CCK-8 assay Cytotoxicity against human HuH7 cells by CCK-8 assay	[PMID: 27704808]
HUVEC	IC₅₀	4.3 μM Compound: ADR	Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay	[PMID: 33097300]
IMR-32	IC₅₀	0.02 μM Compound: Adriamycin	Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay	10.1007/s00044-010-9500-5
IMR-32	IC₅₀	1.7 μM Compound: Adriamycin	Cytotoxicity against human IMR-32 cells assessed as inhibition of cell growth incubated for 30 mins by SRB assay Cytotoxicity against human IMR-32 cells assessed as inhibition of cell growth incubated for 30 mins by SRB assay	[PMID: 30114660]
K562	IC₅₀	0.01 μM Compound: Adriamycin	Antiproliferative activity against human K562 cells after 48 hrs by Alamar blue dye based neubauer hemocytometer method Antiproliferative activity against human K562 cells after 48 hrs by Alamar blue dye based neubauer hemocytometer method	[PMID: 28045256]
K562	IC₅₀	0.01 μM Compound: Adriamycine	Cell growth inhibition of human K562 cells after 48 hrs Cell growth inhibition of human K562 cells after 48 hrs	[PMID: 20546980]
K562	IC₅₀	0.01 μM Compound: Adriamycine	Antiproliferative activity against human K562 cells after 48 hrs Antiproliferative activity against human K562 cells after 48 hrs	[PMID: 20537765]
K562	IC₅₀	0.01 μM Compound: adriamycin	Antiproliferative activity against human K562 cells after 48 hrs Antiproliferative activity against human K562 cells after 48 hrs	[PMID: 17973361]
K562	GI₅₀	0.02 μM Compound: Doxorubicin hydrochloride	Growth inhibition of human K562 cells measured after 3 days by trypan blue assay Growth inhibition of human K562 cells measured after 3 days by trypan blue assay	[PMID: 29565129]
K562	IC₅₀	0.059 μM Compound: ADR	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 26832219]
K562	GI₅₀	0.17 μM Compound: DOX HCl	Growth inhibition against human K562 cells after 72 hrs by inverted microscopy Growth inhibition against human K562 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
K562	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32880456]
K562	IC₅₀	0.22 μM Compound: Adriamycin	Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay	[PMID: 27503681]
K562	IC₅₀	0.3 μM Compound: Adriamycin	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 31904949]
K562	IC₅₀	0.3 μM Compound: ADM	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 29985604]
K562	IC₅₀	0.3 μM Compound: Adriamycin	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 28418245]
K562	IC₅₀	0.3 μM Compound: Dox	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 26506221]
K562	IC₅₀	0.3 μM Compound: adriamycin	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 23806071]
K562	IC₅₀	0.3 μM Compound: ADM	Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay	[PMID: 35993848]
K562	IC₅₀	0.3 μM Compound: Adriamycin	Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay	[PMID: 32840364]
K562	IC₅₀	0.36 μM Compound: ADM	Cytotoxicity against human K562 cells after 2 days by MTT assay Cytotoxicity against human K562 cells after 2 days by MTT assay	[PMID: 21821321]
K562	IC₅₀	0.39 μM Compound: ADR	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 29335204]
K562	IC₅₀	0.43 μM Compound: ADR	Antiproliferative activity against human K562 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human K562 cells after 72 hrs by sulforhodamine B assay	[PMID: 20353152]
K562	IC₅₀	0.47 μM Compound: Adriamycin	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318123]
K562	IC₅₀	0.51 μM Compound: ADM	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 28301155]
K562	IC₅₀	0.57 μM Compound: Adriamycin	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28222318]
K562	IC₅₀	0.59 μM Compound: ADR	Anti-proliferative activity against human K562 cells measured after 72 hrs by MTS assay Anti-proliferative activity against human K562 cells measured after 72 hrs by MTS assay	[PMID: 28068095]
K562	IC₅₀	0.61 μM Compound: ADR	Antiproliferative activity in human K562 cells after 48 hrs by MTT assay Antiproliferative activity in human K562 cells after 48 hrs by MTT assay	[PMID: 28570977]
K562	IC₅₀	0.63 μM Compound: ADM	Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30827866]
K562	IC₅₀	0.74 μM Compound: ADR	Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay	[PMID: 33097300]
K562	IC₅₀	0.83 μM Compound: ADR	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 33132117]
K562	IC₅₀	0.92 μM Compound: ADM	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 35247755]
K562	IC₅₀	0.97 μM Compound: ADM	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29631786]
K562	IC₅₀	1.2 μM Compound: doxorubicin hydrochloride	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 19256529]
K562	IC₅₀	108.4 nM Compound: Adriamycin	Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay	[PMID: 34794817]
K562	IC₅₀	2.35 μM Compound: Dox	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 22318158]
K562	IC₅₀	2.5 μM Compound: Adriamycin	Cytotoxicity against human K562 cells after 4 days by ELISA reader assay Cytotoxicity against human K562 cells after 4 days by ELISA reader assay	[PMID: 19939682]
K562	IC₅₀	4.29 μM Compound: ADM	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 28645831]
K562	IC₅₀	6.23 μM Compound: ADM	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27073052]
K562	IC₅₀	77.7 nM Compound: ADR	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 28333459]
K562	IC₅₀	8.9 μM Compound: Adriamycin	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 25304898]
K562/A02	IC₅₀	10.55 μM Compound: ADR	Cytotoxicity against human K562/A02 cells after 72 hrs by MTT assay Cytotoxicity against human K562/A02 cells after 72 hrs by MTT assay	[PMID: 26832219]
K562/A02	IC₅₀	19.21 μM Compound: ADM	Cytotoxicity against human K562/A02 cells after 2 days by MTT assay Cytotoxicity against human K562/A02 cells after 2 days by MTT assay	[PMID: 21821321]
K562/A02	IC₅₀	23.42 μM Compound: ADR	Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay	[PMID: 33132117]
K562/A02	IC₅₀	23.81 μM Compound: ADR	Antiproliferative activity against human K562/A02 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human K562/A02 cells after 72 hrs by sulforhodamine B assay	[PMID: 20353152]
K562/A02	IC₅₀	24.46 μM Compound: ADR	Anti-proliferative activity against P-gp overexpressing/drug resistant human K562/A02 cells measured after 72 hrs by MTS assay Anti-proliferative activity against P-gp overexpressing/drug resistant human K562/A02 cells measured after 72 hrs by MTS assay	[PMID: 28068095]
K562/A02	IC₅₀	25.04 μM Compound: ADR	Cytotoxicity against human K562/A02 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human K562/A02 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 29335204]
K562/A02	IC₅₀	38.02 μM Compound: ADM	Cytotoxicity against human K562/A02 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27073052]
K562/A02	IC₅₀	53.95 μM Compound: ADM	Cytotoxicity against human K562/A02 cells overexpressing P-gp after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells overexpressing P-gp after 48 hrs by MTT assay	[PMID: 28301155]
K562/A02	IC₅₀	54.22 μM Compound: ADM	Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay	[PMID: 25464884]
K562/A02	IC₅₀	65.57 μM Compound: ADM	Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29631786]
K562/A02	IC₅₀	78.34 μM Compound: ADM	Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay	[PMID: 35247755]
K562/A02	IC₅₀	96.91 μM Compound: ADM	Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay	[PMID: 28645831]
K562/Adr	IC₅₀	18.779 μM Compound: Adriamycin	Antiproliferative activity against human K562/ADR cells after 72 hrs by CCK8 assay Antiproliferative activity against human K562/ADR cells after 72 hrs by CCK8 assay	[PMID: 27503681]
K562/Adr	IC₅₀	31191 nM Compound: Adriamycin	Antiproliferative activity against human K562/Adr cells measured after 72 hrs by SRB assay Antiproliferative activity against human K562/Adr cells measured after 72 hrs by SRB assay	[PMID: 34794817]
K562/Adr	IC₅₀	3310.2 nM Compound: ADR	Antiproliferative activity against human K562/ADR cells after 72 hrs by MTT assay Antiproliferative activity against human K562/ADR cells after 72 hrs by MTT assay	[PMID: 28333459]
KB	IC₅₀	0.01 μM Compound: Doxorubicin.HCl	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 23131338]
KB	GI₅₀	0.13 μM Compound: ADR	Cytotoxicity against human KB cells after 48 hrs by SRB assay Cytotoxicity against human KB cells after 48 hrs by SRB assay	[PMID: 20554354]
KB	GI₅₀	0.13 μM Compound: ADR	Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B based ELISA Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B based ELISA	[PMID: 21402478]
KB	GI₅₀	0.16 μM Compound: ADR	Anticancer activity against human KB cells after 48 hrs by SRB assay Anticancer activity against human KB cells after 48 hrs by SRB assay	[PMID: 20557981]
KB	GI₅₀	0.17 μM Compound: ADR	Cytotoxicity against human KB cells after 48 hrs by SRB assay Cytotoxicity against human KB cells after 48 hrs by SRB assay	[PMID: 20444601]
KB	GI₅₀	0.17 μM Compound: ADR	Cytotoxicity against human KB cells by sulforhodamine B method Cytotoxicity against human KB cells by sulforhodamine B method	[PMID: 21459581]
KB	GI₅₀	0.19 μM Compound: ADR	Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay	[PMID: 21194809]
KB	IC₅₀	0.27 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay	[PMID: 21473608]
KB	IC₅₀	0.28 μM Compound: doxorubicin hydrochloride	Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay	[PMID: 20364867]
KB	IC₅₀	0.57 μM Compound: Adr	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 29182349]
KB	IC₅₀	0.6 μM Compound: Adriamycin	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 21875764]
KB	IC₅₀	0.6 μM Compound: Adriamycin	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 20627721]
KB	IC₅₀	0.84 μM Compound: DOX	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 24686017]
KB	IC₅₀	0.84 μM Compound: DOX	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 22574992]
KB	IC₅₀	1.2 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human KB cells by resazurin microplate assay Cytotoxicity against human KB cells by resazurin microplate assay	[PMID: 21995505]
KB	IC₅₀	1.66 μg/mL Compound: ADR	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 20724170]
KB	IC₅₀	10 μg/mL Compound: adriamycin	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 17512094]
KB	IC₅₀	2.2 μM Compound: Adriamycin	Cytotoxicity against human KB cells incubated for 48 hrs by MTT assay Cytotoxicity against human KB cells incubated for 48 hrs by MTT assay	[PMID: 32394716]
KB	IC₅₀	3.2 μM Compound: Adriamycin	Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31268321]
KB-V1	IC₅₀	1.02 μM Compound: 1	Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay in presence of 24 mM ABC transporter inhibitor verapamil hydrochloride Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay in presence of 24 mM ABC transporter inhibitor verapamil hydrochloride	[PMID: 20133021]
KB-V1	IC₅₀	18.3 μM Compound: 1	Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay	[PMID: 20133021]
KB-V1	IC₅₀	35.6 μM Compound: 1	Cytotoxicity against human vinblastine-resistant KBV1 cells after 48 hrs by MTT assay Cytotoxicity against human vinblastine-resistant KBV1 cells after 48 hrs by MTT assay	[PMID: 20133021]
KB-V1	IC₅₀	59.9 μM Compound: 1	Cytotoxicity against human vinblastine-resistant KBV1 cells after 24 hrs by MTT assay Cytotoxicity against human vinblastine-resistant KBV1 cells after 24 hrs by MTT assay	[PMID: 20133021]
KG-1a	IC₅₀	0.08 μM Compound: ADR	Cytotoxicity against human KG1a cells assessed as decrease in cell proliferation after 48 hrs by MTT assay Cytotoxicity against human KG1a cells assessed as decrease in cell proliferation after 48 hrs by MTT assay	[PMID: 28068601]
KG-1a	IC₅₀	0.82 μM Compound: ADR	Cytotoxicity against human KG1a cells after 72 hrs by MTT assay Cytotoxicity against human KG1a cells after 72 hrs by MTT assay	[PMID: 26832219]
L02	IC₅₀	0.2 μM Compound: ADM	Cytotoxicity against human L02 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human L02 cells assessed as reduction in cell viability by SRB assay	[PMID: 35993848]
L02	IC₅₀	0.5 μM Compound: Adriamycin	Cytotoxicity against human L02 cells after 24 hrs by SRB method Cytotoxicity against human L02 cells after 24 hrs by SRB method	[PMID: 31904949]
L02	IC₅₀	0.7 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human L02 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability by MTT assay	[PMID: 34176266]
L02	IC₅₀	0.79 μM Compound: ADR	Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
L02	IC₅₀	13.5 μM Compound: Adriamycin	Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
L1210	ED₅₀	0.07 μg/mL Compound: Adriamycin	Anticancer activity against mouse L1210 cells assessed as reduction in cell viability for 72 hrs by MTT assay Anticancer activity against mouse L1210 cells assessed as reduction in cell viability for 72 hrs by MTT assay	[PMID: 35367708]
L929	IC₅₀	7.5 μM Compound: Doxorubicin HCl	Antiproliferative activity against mouse L929 cells after 72 hrs by MTT assay Antiproliferative activity against mouse L929 cells after 72 hrs by MTT assay	[PMID: 29884536]
Lewis lung carcinoma cell line	IC₅₀	0.23 μM Compound: adriamycine	Cytotoxicity activity against mouse LLC cells after 48 hrs by MTT assay Cytotoxicity activity against mouse LLC cells after 48 hrs by MTT assay	[PMID: 19618898]
LoVo	IC₅₀	0.11 μM Compound: DOX	Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 24686017]
LoVo	IC₅₀	0.11 μM Compound: DOX	Cytotoxicity against human LoVo cells after 72 hrs by SRB assay Cytotoxicity against human LoVo cells after 72 hrs by SRB assay	[PMID: 22574992]
LoVo	IC₅₀	0.2 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 15387667]
LoVo	GI₅₀	0.24 μM Compound: DOX HCl	Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy	[PMID: 23353738]
LoVo	IC₅₀	13.2 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human doxorubicin-resistant LoVo cells after 72 hrs by MTT assay Cytotoxicity against human doxorubicin-resistant LoVo cells after 72 hrs by MTT assay	[PMID: 15387667]
MCF-10A	GI₅₀	0.04 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF10A cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF10A cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27598688]
MCF-10A	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 29286660]
MCF-10A	IC₅₀	0.86 μM Compound: ADR	Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34992039]
MCF-10A	IC₅₀	0.89 μM Compound: ADR	Cytotoxic activity against human MCF-10A assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxic activity against human MCF-10A assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35390712]
MCF-10A	IC₅₀	0.93 μM Compound: ADM	Cytotoxicity against human MCF10A cells after 72 hrs by cell counting kit-8 analysis Cytotoxicity against human MCF10A cells after 72 hrs by cell counting kit-8 analysis	[PMID: 29174815]
MCF-10A	IC₅₀	1.11 μM Compound: Doxorubicin	Growth inhibition of human MCF10A cells after 72 hrs by CellTiter-Blue assay Growth inhibition of human MCF10A cells after 72 hrs by CellTiter-Blue assay	[PMID: 24153206]
MCF7	IC₅₀	< 0.068 mg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 22142614]
MCF7	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay	10.1007/s00044-012-0423-1
MCF7	GI₅₀	< 0.1 μM Compound: ADR	Growth inhibition of Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay Growth inhibition of Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay	10.1007/s00044-011-9688-z
MCF7	GI₅₀	< 0.1 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 28258796]
MCF7	GI₅₀	< 0.1 μM Compound: ADR	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 26994845]
MCF7	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 20554354]
MCF7	IC₅₀	< 0.1 μM Compound: Adiramycin	Cytotoxicity against human MCF7 cells by SRB method Cytotoxicity against human MCF7 cells by SRB method	[PMID: 24951333]
MCF7	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
MCF7	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31804070]
MCF7	IC₅₀	< 10 μM Compound: Adriamycin	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 35694689]
MCF7	IC₅₀	> 10 μM Compound: adriamicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21090801]
MCF7	GI₅₀	0.00018 μM Compound: Adriamycin	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 31330449]
MCF7	IC₅₀	0.0012 μM Compound: Adiramycin	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay	[PMID: 33940466]
MCF7	GI₅₀	0.054 μM Compound: Adr	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 29102180]
MCF7	GI₅₀	0.054 μM Compound: Adr	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 26741854]
MCF7	IC₅₀	0.075 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Blue assay Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Blue assay	[PMID: 24153206]
MCF7	IC₅₀	0.08 μM Compound: 1	Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay in presence of 1.2 mM BCRP inhibitor fumitremorgin C Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay in presence of 1.2 mM BCRP inhibitor fumitremorgin C	[PMID: 20133021]
MCF7	IC₅₀	0.1 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29286660]
MCF7	GI₅₀	0.13 μM Compound: ADR	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B based ELISA Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B based ELISA	[PMID: 21402478]
MCF7	IC₅₀	0.15 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay	[PMID: 21192108]
MCF7	GI₅₀	0.17 mM Compound: Adriamycin	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 32631569]
MCF7	GI₅₀	0.17 μM Compound: ADR	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 20444601]
MCF7	GI₅₀	0.17 μM Compound: ADR	Cytotoxicity against human MCF7 cells by sulforhodamine B method Cytotoxicity against human MCF7 cells by sulforhodamine B method	[PMID: 21459581]
MCF7	IC₅₀	0.2 μM Compound: ADM	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28749671]
MCF7	GI₅₀	0.23 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition by SRB assay	[PMID: 24507920]
MCF7	IC₅₀	0.39 μM Compound: ADR	Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 20353152]
MCF7	IC₅₀	0.4 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30049584]
MCF7	IC₅₀	0.42 μM Compound: ADR	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30677614]
MCF7	IC₅₀	0.44 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 24686017]
MCF7	IC₅₀	0.44 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 22574992]
MCF7	IC₅₀	0.65 μM Compound: adriamycine	Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19618898]
MCF7	IC₅₀	0.67 μM Compound: ADR	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 35339100]
MCF7	IC₅₀	0.67 μM Compound: ADR	Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
MCF7	EC₅₀	0.7 μM Compound: Adriamycin	Antiproliferative activity against human ER-positive MCF7 cells measured after 48 hrs by MTT assay Antiproliferative activity against human ER-positive MCF7 cells measured after 48 hrs by MTT assay	[PMID: 27344488]
MCF7	IC₅₀	0.7 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 29215886]
MCF7	IC₅₀	0.72 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 33689875]
MCF7	IC₅₀	0.8 μM Compound: Adriamycin	Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay	10.1007/s00044-010-9500-5
MCF7	IC₅₀	0.88 μM Compound: AMD	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25408835]
MCF7	IC₅₀	0.99 μM Compound: Adriamycin	Cytotoxicity against human wild-type MCF7 cells after 72 hrs Cytotoxicity against human wild-type MCF7 cells after 72 hrs	[PMID: 28720329]
MCF7	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31268321]
MCF7	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay	[PMID: 27240278]
MCF7	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30222343]
MCF7	IC₅₀	1 μM Compound: 1	Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay	[PMID: 20133021]
MCF7	IC₅₀	1.02 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34081476]
MCF7	IC₅₀	1.1 μM Compound: ADR	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 33097300]
MCF7	IC₅₀	1.13 μM Compound: ADR	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35390712]
MCF7	IC₅₀	1.2 μM Compound: 4; ADR	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28803046]
MCF7	IC₅₀	1.2 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 34176266]
MCF7	IC₅₀	1.3 μM Compound: 1	Cytotoxicity against human topotecan-resistant MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human topotecan-resistant MCF7 cells after 48 hrs by MTT assay	[PMID: 20133021]
MCF7	IC₅₀	1.3 μM Compound: Adriamycin	Cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 28006904]
MCF7	IC₅₀	1.31 μM Compound: ADR	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34992039]
MCF7	IC₅₀	1.5 μM Compound: doxorubicin hydrochloride	Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay	[PMID: 20364867]
MCF7	IC₅₀	1.65 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21123066]
MCF7	IC₅₀	1.72 μM Compound: Adriamycin	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 29903663]
MCF7	IC₅₀	15 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human MCF7 cells by resazurin microplate assay Cytotoxicity against human MCF7 cells by resazurin microplate assay	[PMID: 21995505]
MCF7	IC₅₀	15.8 μM Compound: Adriamycin	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
MCF7	IC₅₀	18.9 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 4 days by MTT assay Cytotoxicity against human MCF7 cells after 4 days by MTT assay	[PMID: 20619511]
MCF7	IC₅₀	2.1 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay	[PMID: 19939682]
MCF7	IC₅₀	2.3 μM Compound: ADR	Antiproliferative activity in human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity in human MCF7 cells after 48 hrs by MTT assay	[PMID: 28570977]
MCF7	IC₅₀	2.5 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 32394716]
MCF7	IC₅₀	2.78 μM Compound: Doxorubicin.HCl	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25529734]
MCF7	IC₅₀	22.2 nM Compound: Adriamycin	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 27213819]
MCF7	IC₅₀	25.6 nM Compound: Adriamycin	Cytotoxicity in human MCF7 assessed as inhibition in cell growth measured after 24 hrs by MTT assay Cytotoxicity in human MCF7 assessed as inhibition in cell growth measured after 24 hrs by MTT assay	[PMID: 35084853]
MCF7	IC₅₀	25.9 μM Compound: Adriamycin	Antiproliferative activity against human MCF7 cells by SRB assay Antiproliferative activity against human MCF7 cells by SRB assay	[PMID: 32688198]
MCF7	IC₅₀	27.92 μM Compound: ADR	Antiproliferative activity against human MCF7/ADR cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34992039]
MCF7	IC₅₀	28.4 μM Compound: ADR	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34649064]
MCF7	IC₅₀	3.2 μM Compound: Adriamycin	Cytotoxicity against human MCF-7 cells assessed as cell viability inhibition for 48 hrs by MTT assay Cytotoxicity against human MCF-7 cells assessed as cell viability inhibition for 48 hrs by MTT assay	[PMID: 33913326]
MCF7	IC₅₀	3.23 ng/mL Compound: 2b	Concentration required to inhibit proliferation of human mammary adenocarcinoma MCF-7 cell line was determined using MTT assay Concentration required to inhibit proliferation of human mammary adenocarcinoma MCF-7 cell line was determined using MTT assay	[PMID: 15324908]
MCF7	IC₅₀	4.6 μM Compound: Doxorubicin HCl	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29884536]
MCF7	IC₅₀	4.9 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay	[PMID: 21473608]
MCF7	IC₅₀	44.8 nM Compound: Adriamycin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28763646]
MCF7	IC₅₀	44.82 nM Compound: Adriamycin	Antiproliferative activity against human MCF7 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 to 72 hrs by MTT assay	[PMID: 29754076]
MCF7	IC₅₀	5.1 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21875764]
MCF7	IC₅₀	5.1 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 20627721]
MCF7	IC₅₀	5.3 μM Compound: Adriamycin	Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 28006904]
MCF7	IC₅₀	5.31 μM Compound: Adriamycin	Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
MCF7	IC₅₀	5.75 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 3 days Cytotoxicity against human MCF7 cells after 3 days	[PMID: 19954977]
MCF7	GI₅₀	50.2 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay	[PMID: 32791404]
MCF7	IC₅₀	6.2 μM Compound: 1	Cytotoxicity against human topotecan-resistant MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human topotecan-resistant MCF7 cells after 24 hrs by MTT assay	[PMID: 20133021]
MCF7	IC₅₀	9.2 μM Compound: Adriamycin	Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 28006904]
MCF7	IC₅₀	94.1 μM Compound: AMD	Cytotoxicity against adriamycin-resistant human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against adriamycin-resistant human MCF7 cells after 48 hrs by MTT assay	[PMID: 25408835]
MDA-MB-231	IC₅₀	< 0.068 mg/mL Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 22142614]
MDA-MB-231	GI₅₀	0.07 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay	[PMID: 29878761]
MDA-MB-231	GI₅₀	0.08 μM Compound: Adriamycin	Growth inhibition of human MDA-MB-231 cells by SRB assay Growth inhibition of human MDA-MB-231 cells by SRB assay	[PMID: 36040099]
MDA-MB-231	GI₅₀	0.09 μM Compound: doxorubicin hydrochloride	Antitumor activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antitumor activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 21718029]
MDA-MB-231	GI₅₀	0.12 μM Compound: Adr	Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay	[PMID: 29102180]
MDA-MB-231	IC₅₀	0.15 μM Compound: ADR	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method	[PMID: 35302779]
MDA-MB-231	GI₅₀	0.15 μM Compound: ADR	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 31668073]
MDA-MB-231	IC₅₀	0.19 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33774342]
MDA-MB-231	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34282909]
MDA-MB-231	IC₅₀	0.2 μM Compound: ADM	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35380848]
MDA-MB-231	IC₅₀	0.3 μM Compound: Adriamycin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 31397570]
MDA-MB-231	IC₅₀	0.3 μM Compound: ADM	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay	[PMID: 35993848]
MDA-MB-231	IC₅₀	0.37 μM Compound: Adriamycin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 35121401]
MDA-MB-231	IC₅₀	0.39 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay	[PMID: 24153206]
MDA-MB-231	IC₅₀	0.4 μM Compound: ADR	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 35762988]
MDA-MB-231	IC₅₀	0.4 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
MDA-MB-231	IC₅₀	0.54 μM Compound: Doxorubicin.HCl	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
MDA-MB-231	IC₅₀	0.6 μM Compound: Adriamycin	Anti-proliferative activity against human MDA-MB-231 cells by XTT assay Anti-proliferative activity against human MDA-MB-231 cells by XTT assay	[PMID: 25442319]
MDA-MB-231	IC₅₀	0.8 μM Compound: ADR	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay	[PMID: 30739826]
MDA-MB-231	IC₅₀	0.82 μM Compound: ADR	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34992039]
MDA-MB-231	IC₅₀	0.84 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells after 2 days Cytotoxicity against human MDA-MB-231 cells after 2 days	[PMID: 21419530]
MDA-MB-231	IC₅₀	0.86 μM Compound: ADR	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35390712]
MDA-MB-231	IC₅₀	1.16 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells after 3 days Cytotoxicity against human MDA-MB-231 cells after 3 days	[PMID: 19954977]
MDA-MB-231	IC₅₀	1.2 μM Compound: DOX.HCl	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28445049]
MDA-MB-231	IC₅₀	1.45 μM Compound: Dox	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 22318158]
MDA-MB-231	IC₅₀	1.67 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 19836231]
MDA-MB-231	IC₅₀	1.8 μM Compound: 4; ADR	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28803046]
MDA-MB-231	IC₅₀	2.19 μM Compound: Adriamycin	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29903663]
MDA-MB-231	IC₅₀	2.26 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 21144747]
MDA-MB-231	EC₅₀	2.3 μM Compound: Adriamycin	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 27344488]
MDA-MB-231	IC₅₀	2.94 μM Compound: ADR	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 30837097]
MDA-MB-231	IC₅₀	3 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 29286660]
MDA-MB-231	IC₅₀	3.15 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20093033]
MDA-MB-231	IC₅₀	3.6 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay	[PMID: 27707625]
MDA-MB-231	IC₅₀	4.06 μM Compound: Doxorubicin.HCl	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25529734]
MDA-MB-231	IC₅₀	4.4 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay	[PMID: 20619511]
MDA-MB-231	IC₅₀	5.18 μM Compound: Adriamycin	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay	[PMID: 31398033]
MDA-MB-435	GI₅₀	< 0.1 μM Compound: ADR	Anticancer activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Anticancer activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 26994845]
MDA-MB-435	GI₅₀	< 0.1 μM Compound: Adriamycin	Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition by sulforhodamine B assay Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition by sulforhodamine B assay	[PMID: 35694689]
MDA-MB-435	IC₅₀	0.77 μg/mL Compound: Dox	Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by MTT assay Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by MTT assay	10.1007/s00044-013-0486-7
MDA-MB-435	IC₅₀	0.93 μg/mL Compound: Dox	Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by SRB assay Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by SRB assay	10.1007/s00044-013-0486-7
MDA-MB-436	IC₅₀	2.03 μM Compound: Adriamycin	Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay	[PMID: 31398033]
MDA-MB-468	EC₅₀	0.7 μM Compound: Adriamycin	Antiproliferative activity against human ER-triple negative MDA-MB-468 cells measured after 48 hrs by MTT assay Antiproliferative activity against human ER-triple negative MDA-MB-468 cells measured after 48 hrs by MTT assay	[PMID: 27344488]
MDA-MB-468	GI₅₀	10.5 μM Compound: ADR	Anticancer activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Anticancer activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 26994845]
MDA-MB-468	IC₅₀	2.15 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay	[PMID: 27707625]
MG-63	IC₅₀	2.2 μM Compound: Adriamycin	Cytotoxicity against human MG63 cells by MTT assay Cytotoxicity against human MG63 cells by MTT assay	[PMID: 27704808]
MG-63	IC₅₀	3.4 μM Compound: Adriamycin	Cytotoxicity against human MG63 cells by MTT assay Cytotoxicity against human MG63 cells by MTT assay	[PMID: 23477504]
MG-63	IC₅₀	5.2 μM Compound: Adriamycin	Growth inhibition of human MG63 cells by MTT method Growth inhibition of human MG63 cells by MTT method	[PMID: 25611131]
MGC-803	IC₅₀	0.2 μM Compound: ADM	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 29985604]
MGC-803	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 26506221]
MGC-803	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human MGC803 cells after 24 hrs by SRB method Cytotoxicity against human MGC803 cells after 24 hrs by SRB method	[PMID: 31904949]
MGC-803	IC₅₀	0.48 μM Compound: Adriamycin	Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 35367708]
MGC-803	IC₅₀	0.71 μM Compound: ADM	Growth inhibition of human MGC803 cells after 72 hrs by MTT assay Growth inhibition of human MGC803 cells after 72 hrs by MTT assay	[PMID: 25064351]
MGC-803	IC₅₀	2.53 μM Compound: Adriamycin	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 21144747]
MGC-803	IC₅₀	2.56 μM Compound: Dox	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 22318158]
MIA PaCa-2	IC₅₀	0.25 μM Compound: Adriamycin	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth by CCK-8 assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 36583957]
MOLT-4	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay	10.1007/s00044-012-0423-1
MOLT-4	IC₅₀	0.07 μM Compound: Dox	Cytotoxicity against human MOLT4 cells after 48 hrs by Alamar blue assay Cytotoxicity against human MOLT4 cells after 48 hrs by Alamar blue assay	[PMID: 25064348]
MV4-11	IC₅₀	0.006 μM Compound: Doxorubicin HCl	Antiproliferative activity against Homo sapiens (human) MV411 cells after 72 hr by MTT assay Antiproliferative activity against Homo sapiens (human) MV411 cells after 72 hr by MTT assay	10.1007/s00044-012-0443-x
MV4-11	IC₅₀	0.006 μM Compound: Doxorubicin HCl	Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24686018]
MV4-11	IC₅₀	0.006 μM Compound: Doxorubicin HCl	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 22748378]
MV4-11	IC₅₀	0.14 μM Compound: Adriamycin	Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay	[PMID: 33356258]
NB-4	IC₅₀	0.4 μM Compound: Adriamycin	Cytotoxicity against human NB4 cells after 72 hrs by MTT assay Cytotoxicity against human NB4 cells after 72 hrs by MTT assay	[PMID: 28418245]
NCI/ADR-RES	EC₅₀	> 10 μM Compound: Adriamycin	Antiproliferative activity against human MCF7/ADR cells measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells measured after 48 hrs by MTT assay	[PMID: 27344488]
NCI/ADR-RES	IC₅₀	> 50 μM Compound: Adriamycin	Cytotoxicity against human MCF7/ADR cells after 72 hrs Cytotoxicity against human MCF7/ADR cells after 72 hrs	[PMID: 28720329]
NCI/ADR-RES	GI₅₀	0.52 μM Compound: Adr	Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay	[PMID: 26741854]
NCI/ADR-RES	GI₅₀	0.54 μM Compound: Adr	Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay	[PMID: 29102180]
NCI/ADR-RES	IC₅₀	2.9 μM Compound: Adriamycin	Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay	[PMID: 29286660]
NCI/ADR-RES	IC₅₀	232.5 μM Compound: ADR	Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34649064]
NCI/ADR-RES	IC₅₀	24.92 μM Compound: ADR	Antiproliferative activity against human NCI-ADR-RES cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-ADR-RES cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35390712]
NCI/ADR-RES	IC₅₀	39.52 μM Compound: ADR	Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay	[PMID: 30677614]
NCI/ADR-RES	IC₅₀	44.9 μM Compound: ADR	Antiproliferative activity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay	[PMID: 20353152]
NCI/ADR-RES	IC₅₀	50.74 μM Compound: Adriamycin	Growth inhibition of human MCF7/ADR cells after 48 hrs by MTT assay Growth inhibition of human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 29903663]
NCI/ADR-RES	IC₅₀	5300 nM Compound: adriamycin	Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 25208345]
NCI/ADR-RES	IC₅₀	54749.19 nM Compound: Adriamycin	Antiproliferative activity against human MCF7/ADR cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells after 48 to 72 hrs by MTT assay	[PMID: 29754076]
NCI/ADR-RES	IC₅₀	54750 nM Compound: Adriamycin	Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 28763646]
NCI/ADR-RES	IC₅₀	58.8 μM Compound: Adriamycin	Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay	[PMID: 27240278]
NCI/ADR-RES	IC₅₀	8153 nM Compound: Adriamycin	Cytotoxicity against P-gp overexpressing human MCF7/ADR cells assessed as reduction in cell growth after 24 hrs by MTT assay Cytotoxicity against P-gp overexpressing human MCF7/ADR cells assessed as reduction in cell growth after 24 hrs by MTT assay	[PMID: 27213819]
NCI/ADR-RES	IC₅₀	8216 nM Compound: Adriamycin	Cytotoxicity in human NCI-ADR-RES assessed as inhibition in cell growth measured after 24 hrs by MTT assay Cytotoxicity in human NCI-ADR-RES assessed as inhibition in cell growth measured after 24 hrs by MTT assay	[PMID: 35084853]
NCI/ADR-RES	IC₅₀	85.14 μM Compound: ADR	Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 35339100]
NCI-H1299	IC₅₀	0.8 μM Compound: Adriamycin	Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31268321]
NCI-H1299	IC₅₀	4.7 μM Compound: Adriamycin	Cytotoxicity against human NCI-H12199 cells assessed as cell viability inhibition for 48 hrs by MTT assay Cytotoxicity against human NCI-H12199 cells assessed as cell viability inhibition for 48 hrs by MTT assay	[PMID: 33913326]
NCI-H187	IC₅₀	0.086 μM Compound: doxorubicin hydrochloride	Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay	[PMID: 20364867]
NCI-H187	IC₅₀	0.23 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay	[PMID: 21473608]
NCI-H187	IC₅₀	0.25 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human NCI-H187 cells by resazurin microplate assay Cytotoxicity against human NCI-H187 cells by resazurin microplate assay	[PMID: 21995505]
NCI-H1975	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human NCI-H1975 cells after 24 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H1975 cells after 24 hrs by sulforhodamine B assay	[PMID: 28418245]
NCI-H1975	IC₅₀	0.8 μM Compound: Dox	Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 26506221]
NCI-H226	GI₅₀	< 0.1 μM Compound: ADR	Anticancer activity against human NCI-H226 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Anticancer activity against human NCI-H226 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 26994845]
NCI-H226	IC₅₀	0.3 μM Compound: Adriamycin	Antiproliferative activity against human NCI-H226 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Antiproliferative activity against human NCI-H226 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 31397570]
NCI-H23	GI₅₀	0.08 μM Compound: Adriamycin	Growth inhibition of human NCI-H23 cells by SRB assay Growth inhibition of human NCI-H23 cells by SRB assay	[PMID: 36040099]
NCI-H23	GI₅₀	0.08 μM Compound: Adriamycin	Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay	[PMID: 29878761]
NCI-H23	IC₅₀	0.09 μM Compound: ADR	Cytotoxicity against human NCI-H23 cells by colorimetric method Cytotoxicity against human NCI-H23 cells by colorimetric method	[PMID: 32916298]
NCI-H23	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 31668073]
NCI-H23	IC₅₀	0.16 μM Compound: ADR	Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method	[PMID: 35302779]
NCI-H23	IC₅₀	0.49 μM Compound: Adriamycin	Anti-proliferative activity against human NCI-H23 cells by XTT assay Anti-proliferative activity against human NCI-H23 cells by XTT assay	[PMID: 25442319]
NCI-H3255	IC₅₀	1.5 μM Compound: Adriamycin	Cytotoxicity against human NCI-H3255 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H3255 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34797067]
NCI-H358	IC₅₀	< 5 μM Compound: Adriamycin	Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
NCI-H446	IC₅₀	1.7 μM Compound: Adriamycin	Cytotoxicity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34797067]
NCI-H460	IC₅₀	0.24 μM Compound: adriamycin	Cytotoxic activity against human H460 cells by MTT method Cytotoxic activity against human H460 cells by MTT method	[PMID: 25739048]
NCI-H460	IC₅₀	0.98 μM Compound: Adriamycin	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by MTT assay	[PMID: 26933756]
NCI-H460	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human NCI-H460 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay	[PMID: 28206772]
NCI-N87	IC₅₀	0.71 μM Compound: Adriamycin	Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
NIH3T3	IC₅₀	0.34 μM Compound: ADR	Cytotoxicity against mouse 3T3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse 3T3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31977207]
NIH3T3	IC₅₀	0.36 μM Compound: ADR	Cytotoxicity against mouse 3T3 cells measured after 72 hrs by MTT assay Cytotoxicity against mouse 3T3 cells measured after 72 hrs by MTT assay	[PMID: 30739826]
NIH3T3	IC₅₀	1.08 μM Compound: DOX	Cytotoxicity against BALB mouse 3T3 cells after 72 hrs by SRB assay Cytotoxicity against BALB mouse 3T3 cells after 72 hrs by SRB assay	[PMID: 22574992]
NUGC-3	GI₅₀	0.07 μM Compound: Adriamycin	Cytotoxicity against human NUGC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay Cytotoxicity against human NUGC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay	[PMID: 29878761]
NUGC-3	GI₅₀	0.08 μM Compound: Adriamycin	Growth inhibition of human NUGC-3 cells by SRB assay Growth inhibition of human NUGC-3 cells by SRB assay	[PMID: 36040099]
NUGC-3	IC₅₀	0.15 μM Compound: ADR	Cytotoxicity against human NUGC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method Cytotoxicity against human NUGC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method	[PMID: 35302779]
NUGC-3	GI₅₀	0.15 μM Compound: ADR	Cytotoxicity against human NUGC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human NUGC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 31668073]
NUGC-3	IC₅₀	0.38 μM Compound: Adriamycin	Anti-proliferative activity against human NUGC3 cells by XTT assay Anti-proliferative activity against human NUGC3 cells by XTT assay	[PMID: 25442319]
OS-RC-2	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human OS-RC2 cells by MTT assay Cytotoxicity against human OS-RC2 cells by MTT assay	[PMID: 20627721]
OS-RC-2	IC₅₀	< 1.3 μM Compound: Adriamycin	Cytotoxicity against human OS-RC2 cells by MTT assay Cytotoxicity against human OS-RC2 cells by MTT assay	[PMID: 21875764]
OVCAR-3	GI₅₀	< 0.1 μM Compound: Adriamycin	Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by sulforhodamine B assay Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by sulforhodamine B assay	[PMID: 35694689]
OVCAR-8	GI₅₀	0.15 μM Compound: ADR	Cytotoxicity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay	[PMID: 21194809]
P388	IC₅₀	0.3 μM Compound: Adriamycin	Cytotoxicity against mouse p388 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse p388 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33301677]
PANC-1	GI₅₀	0.24 μM Compound: DOX HCl	Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
PANC-1	IC₅₀	0.48 μM Compound: Adriamycin	Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay	[PMID: 29656202]
PANC-1	IC₅₀	0.9 μM Compound: ADM	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35380848]
PANC-1	IC₅₀	1.7 μM Compound: Adriamycin	Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay	[PMID: 29656202]
PANC-1	IC₅₀	2.11 μM Compound: ADR	Antiproliferative activity against human PANC1 cells after 72 hrs by MTT assay Antiproliferative activity against human PANC1 cells after 72 hrs by MTT assay	[PMID: 30006167]
PC-3	GI₅₀	< 0.1 μM Compound: Adriamycin	Anticancer activity against human PC-3 cells assessed as cell growth inhibition by sulforhodamine B assay Anticancer activity against human PC-3 cells assessed as cell growth inhibition by sulforhodamine B assay	[PMID: 35694689]
PC-3	IC₅₀	< 1 μM Compound: Adriamycin	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
PC-3	IC₅₀	0.02 μM Compound: Adriamycin	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 25259515]
PC-3	IC₅₀	0.09 μM Compound: ADR	Cytotoxicity against human PC3 cells by colorimetric method Cytotoxicity against human PC3 cells by colorimetric method	[PMID: 32916298]
PC-3	GI₅₀	0.09 μM Compound: Adriamycin	Growth inhibition of human PC-3 cells by SRB assay Growth inhibition of human PC-3 cells by SRB assay	[PMID: 36040099]
PC-3	GI₅₀	0.09 μM Compound: Adriamycin	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay	[PMID: 29878761]
PC-3	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 31668073]
PC-3	IC₅₀	0.16 μM Compound: ADR	Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method	[PMID: 35302779]
PC-3	GI₅₀	0.16 μM Compound: ADR	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 20554354]
PC-3	GI₅₀	0.16 μM Compound: ADR	Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 21194809]
PC-3	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34282909]
PC-3	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by SRB assay	[PMID: 32840364]
PC-3	IC₅₀	0.38 μM Compound: Doxorubicin hydrochloride	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33774342]
PC-3	IC₅₀	0.4 μM Compound: Adriamycin	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34797067]
PC-3	IC₅₀	0.4 μM Compound: Adriamycin	Cytotoxicity against human PC-3 cells assessed as cell viability inhibition for 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as cell viability inhibition for 48 hrs by MTT assay	[PMID: 33913326]
PC-3	IC₅₀	0.4 μM Compound: ADR	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 35762988]
PC-3	IC₅₀	0.42 μM Compound: Adriamycin	Cytotoxicity against human PC3 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability by MTT assay	[PMID: 29215886]
PC-3	IC₅₀	0.5 μM Compound: Adriamycin	Anti-proliferative activity against human PC3 cells by XTT assay Anti-proliferative activity against human PC3 cells by XTT assay	[PMID: 25442319]
PC-3	IC₅₀	0.68 μM Compound: Adriamycin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 21123066]
PC-3	IC₅₀	0.8 μM Compound: Adriamycin	Cytotoxicity against human PC3 cells after 24 hrs by MTT assay Cytotoxicity against human PC3 cells after 24 hrs by MTT assay	[PMID: 30049584]
PC-3	IC₅₀	0.8 μM Compound: ADM	Growth inhibition of human PC3 cells after 72 hrs by MTT assay Growth inhibition of human PC3 cells after 72 hrs by MTT assay	[PMID: 25064351]
PC-3	IC₅₀	1 μM Compound: ADM	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29985604]
PC-3	GI₅₀	1.1 μM Compound: Doxorubicin hydrochloride	Growth inhibition of human PC3 cells by colorimetric MTT assay Growth inhibition of human PC3 cells by colorimetric MTT assay	[PMID: 25736997]
PC-3	IC₅₀	1.18 μM Compound: Dox	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 22318158]
PC-3	GI₅₀	1.81 μM Compound: ADR	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 20444601]
PC-3	GI₅₀	1.81 μM Compound: ADR	Cytotoxicity against human PC3 cells by sulforhodamine B method Cytotoxicity against human PC3 cells by sulforhodamine B method	[PMID: 21459581]
PC-3	IC₅₀	11.74 μM Compound: Adriamycin	Cytotoxicity against human PC3 cells after 24 hrs by MTT assay Cytotoxicity against human PC3 cells after 24 hrs by MTT assay	[PMID: 25226363]
PC-3	IC₅₀	15.17 μM Compound: Adriamycin	Cytotoxicity against docetaxel-resistant human PC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against docetaxel-resistant human PC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318123]
PC-3	IC₅₀	16.89 μM Compound: Adriamycin	Antiproliferative activity against paclitaxel-resistant human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against paclitaxel-resistant human PC3 cells after 48 hrs by MTT assay	[PMID: 28222318]
PLC-PRF-5	IC₅₀	1.9 μM Compound: Adriamycin	Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
QG-56	IC₅₀	2.5 μM Compound: Adriamycin	Cytotoxicity against human QG56 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human QG56 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318975]
QG-56	IC₅₀	2.5 μM Compound: Adriamycin	Cytotoxicity against human QG56 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human QG56 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26810315]
SAOS-2	IC₅₀	4.2 μM Compound: Adriamycin	Growth inhibition of human Saos2 cells by MTT method Growth inhibition of human Saos2 cells by MTT method	[PMID: 25611131]
SF-126	IC₅₀	0.26 μM Compound: ADR	Antiproliferative activity against human SF126 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human SF126 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31977207]
SGC-7901	IC₅₀	0.078 μg/mL Compound: Doxorubicin hydrochloride	Cytotoxicity against human SGC7901 cells assessed as cell mortality after 20 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as cell mortality after 20 hrs by MTT assay	[PMID: 21296573]
SGC-7901	IC₅₀	0.078 μg/mL Compound: Doxorubicin hydrochloride	Cytotoxicity against human SGC7901 cells after 20 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 20 hrs by MTT assay	[PMID: 21247667]
SGC-7901	IC₅₀	0.72 μM Compound: Adriamycin	Anticancer activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Anticancer activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 35367708]
SGC-7901	IC₅₀	4.12 μM Compound: ADM	Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 29232583]
SH-SY5Y	IC₅₀	0.1 μM Compound: ADM	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 29985604]
SH-SY5Y	IC₅₀	0.1 μM Compound: Adriamycin	Cytotoxicity against human SH-SY5Y cells after 24 hrs by SRB method Cytotoxicity against human SH-SY5Y cells after 24 hrs by SRB method	[PMID: 31904949]
SH-SY5Y	IC₅₀	0.5 μM Compound: Adriamycin	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability by SRB assay	[PMID: 32840364]
SiHa	GI₅₀	0.15 μM Compound: ADR	Cytotoxicity against human SiHa cells after 48 hrs by SRB assay Cytotoxicity against human SiHa cells after 48 hrs by SRB assay	[PMID: 20554354]
SiHa	GI₅₀	0.17 μM Compound: ADR	Cytotoxicity against human SiHa cells after 48 hrs by SRB assay Cytotoxicity against human SiHa cells after 48 hrs by SRB assay	[PMID: 20444601]
SiHa	GI₅₀	0.17 μM Compound: ADR	Cytotoxicity against human SiHa cells by sulforhodamine B method Cytotoxicity against human SiHa cells by sulforhodamine B method	[PMID: 21459581]
SiHa	GI₅₀	1.9 μM Compound: ADR	Anticancer activity against human SiHa cells after 48 hrs by SRB assay Anticancer activity against human SiHa cells after 48 hrs by SRB assay	[PMID: 20557981]
SK-BR-3	GI₅₀	65.5 nM Compound: Doxorubicin HCl	Growth inhibition of human SKBR3 cells after 72 hrs by SRB assay Growth inhibition of human SKBR3 cells after 72 hrs by SRB assay	[PMID: 22607205]
SMMC-7721	IC₅₀	0.46 μM Compound: Adriamycin	Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 35367708]
SMMC-7721	IC₅₀	0.66 μM Compound: Adriamycin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 29215886]
SMMC-7721	IC₅₀	0.8 μM Compound: Adriamycin	Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31268321]
SMMC-7721	IC₅₀	0.8 μM Compound: Adriamycin	Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31117521]
SMMC-7721	IC₅₀	1.1 μM Compound: Adriamycin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
SMMC-7721	IC₅₀	2.2 μM Compound: Adriamycin	Cytotoxicity against human SMMC7721 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay	[PMID: 28206772]
SMMC-7721	IC₅₀	2.24 μM Compound: Adriamycin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 26933756]
SMMC-7721	IC₅₀	2.67 μM Compound: ADM	Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30739827]
SMMC-7721	IC₅₀	2.67 μM Compound: ADM	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 29232583]
SNU1	IC₅₀	2.01 μM Compound: Adriamycin	Anticancer activity against human SNU1 cells assessed as reduction in cell viability for 72 hrs by MTT assay Anticancer activity against human SNU1 cells assessed as reduction in cell viability for 72 hrs by MTT assay	[PMID: 35367708]
SU.86.86	IC₅₀	0.33 μM Compound: Adriamycin	Cytotoxicity against human SU-86-86 cells assessed as inhibition of cell growth by CCK-8 assay Cytotoxicity against human SU-86-86 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 36583957]
SW-620	IC₅₀	< 5 μM Compound: Adriamycin	Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
SW-620	IC₅₀	0.09 μM Compound: ADR	Cytotoxicity against human SW620 cells by colorimetric method Cytotoxicity against human SW620 cells by colorimetric method	[PMID: 32916298]
SW-620	IC₅₀	1.2 μM Compound: Adriamycin	Cytotoxicity in human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31268321]
T47D	IC₅₀	0.04 μM Compound: ADM	Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay	[PMID: 26866967]
T47D	IC₅₀	0.25 μM Compound: Adriamycin	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 28384547]
T47D	IC₅₀	0.3 μM Compound: Adriamycin	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 28068603]
T47D	IC₅₀	0.31 μM Compound: Adriamycin	Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay	[PMID: 29402741]
T47D	IC₅₀	0.31 μM Compound: Adriamycin	Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay	[PMID: 30262132]
T47D	IC₅₀	0.34 μM Compound: Adriamycin	Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
T47D	IC₅₀	0.41 μM Compound: Adriamycin	Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
T47D	IC₅₀	0.84 μM Compound: Adriamycin	Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay	[PMID: 29510948]
T47D	IC₅₀	0.84 μM Compound: ADM	Cytotoxicity against human T47D cells after 72 hrs by cell counting kit-8 analysis Cytotoxicity against human T47D cells after 72 hrs by cell counting kit-8 analysis	[PMID: 29174815]
T47D	IC₅₀	1.29 μM Compound: Adriamycin	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 28633898]
T47D	IC₅₀	1.34 μM Compound: Adriamycin	Cytotoxicity against human T47D cells after 3 days by CCK8 assay Cytotoxicity against human T47D cells after 3 days by CCK8 assay	[PMID: 26927425]
T47D	IC₅₀	1.34 μM Compound: Adriamycin	Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay	[PMID: 26945111]
T47D	IC₅₀	1.34 μM Compound: Adriamycin	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 27643560]
T47D	IC₅₀	1.42 μM Compound: Adriamycin	Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
T47D	IC₅₀	1.48 μM Compound: Adriamycin	Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
T47D	IC₅₀	1.5 μM Compound: Adriamycin	Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
T47D	IC₅₀	2.18 μM Compound: Adriamycin	Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay	[PMID: 27707625]
T47D	IC₅₀	2.9 μM Compound: Adriamycin	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 26988802]
T47D	IC₅₀	3.12 μM Compound: Adriamycin	Cytotoxicity against human T47D cells after 4 days by CCK-8 assay Cytotoxicity against human T47D cells after 4 days by CCK-8 assay	[PMID: 25062006]
THP-1	IC₅₀	0.02 μM Compound: Adriamycin	Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay	10.1039/C5MD00289C
U-118-MG	IC₅₀	0.09 μM Compound: ADR	Antiproliferative activity against human U118MG cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human U118MG cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31977207]
U-251	IC₅₀	0.157 μM Compound: Adriamycin	Cytotoxicity against human U251 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay Cytotoxicity against human U251 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay	[PMID: 34237623]
U-251	IC₅₀	2.8 μM Compound: Adriamycin	Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31268321]
U-251	IC₅₀	2.9 μM Compound: Adriamycin	Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31117521]
U-251	IC₅₀	48 μM Compound: ADR	Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31977207]
U-87MG ATCC	IC₅₀	0.1 μM Compound: Adriamycin	Cytotoxicity against human U87 cells after 24 hrs by SRB method Cytotoxicity against human U87 cells after 24 hrs by SRB method	[PMID: 31904949]
U-87MG ATCC	IC₅₀	0.11 μM Compound: Doxorubicin.HCl	Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30223117]
U-87MG ATCC	IC₅₀	0.15 μM Compound: ADR	Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31977207]
U-87MG ATCC	IC₅₀	0.16 μM Compound: ADR	Antiproliferative activity against human U87 cells after 72 hrs by MTT assay Antiproliferative activity against human U87 cells after 72 hrs by MTT assay	[PMID: 30006167]
U-87MG ATCC	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against human U87 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human U87 cells assessed as reduction in cell viability by SRB assay	[PMID: 32840364]
U-87MG ATCC	IC₅₀	0.57 μM Compound: Adriamycin	Anticancer activity against human U87 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Anticancer activity against human U87 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 35367708]
U-87MG ATCC	IC₅₀	1.1 μM Compound: Adriamycin	Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31117521]
U-87MG ATCC	IC₅₀	4.28 μM Compound: ADM	Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30739827]
UACC-62	GI₅₀	0.25 μg/mL Compound: Doxorubicin	Cytotoxicity against human UACC62 cells assessed as growth inhibition by SRB assay Cytotoxicity against human UACC62 cells assessed as growth inhibition by SRB assay	[PMID: 24507920]
Vero	GI₅₀	0.02 μM Compound: ADR	Cytotoxicity against African green monkey Vero cells after 72 hrs by sulforhodamine B assay Cytotoxicity against African green monkey Vero cells after 72 hrs by sulforhodamine B assay	[PMID: 28778369]
Vero	GI₅₀	19 μM Compound: Adriamycin	Cytotoxicity against African green monkey Vero cells after 48 hrs by SRB assay Cytotoxicity against African green monkey Vero cells after 48 hrs by SRB assay	[PMID: 28258796]
Vero	GI₅₀	2 μM Compound: ADR	Cytotoxicity against African green monkey Vero cells assessed as total inhibition of cell growth after 72 hrs by sulforhodamine B assay Cytotoxicity against African green monkey Vero cells assessed as total inhibition of cell growth after 72 hrs by sulforhodamine B assay	[PMID: 28778369]
WI-38	IC₅₀	0.08 μM Compound: Adriamycin	Cytotoxicity against human WI38 cells after 72 hrs by CCK8 assay Cytotoxicity against human WI38 cells after 72 hrs by CCK8 assay	[PMID: 27997206]
YAPC	IC₅₀	0.31 μM Compound: Adriamycin	Cytotoxicity against human YAPC cells assessed as inhibition of cell growth by CCK-8 assay Cytotoxicity against human YAPC cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 36583957]
ZR-75-1	GI₅₀	< 0.1 μM Compound: ADR	Anticancer activity against human ZR-75-1 cells after 48 hrs by SRB assay Anticancer activity against human ZR-75-1 cells after 48 hrs by SRB assay	[PMID: 20557981]
ZR-75-1	GI₅₀	0.12 μM Compound: ADR	Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay	[PMID: 20554354]
ZR-75-1	GI₅₀	1.79 μM Compound: ADR	Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay	[PMID: 20444601]
ZR-75-1	GI₅₀	1.79 μM Compound: ADR	Cytotoxicity against human ZR-75-1 cells by sulforhodamine B method Cytotoxicity against human ZR-75-1 cells by sulforhodamine B method	[PMID: 21459581]

In Vitro

Doxorubicin hydrochloride (1-8 μM; 24 and 48 hours) decreases the viability of MCF-10F, MCF-7 and MDA-MB-231 cells in a time- and dose-dependent manner^[4].
Doxorubicin hydrochloride (1 μM; 3 and 24 hours) results in Hct-116 human colon carcinoma cells reduction in G0/G1 phase and accumulation in G2 phase^[5].
Doxorubicin hydrochloride (1 μM for MCF-10F and MDA-MB-231 cells, 4 μM for MCF-7 cells; 48 hours) induces apoptosis by upregulating Bax, caspase-8 and caspase-3 and downregulation of Bcl-2 protein expression^[4].
Doxorubicin hydrochloride (5 μM; 10-30 min) can be accumulated in B16-F10 melanoma cell line CRL-6475 in a time-dependent manner, and can be detected by green or red fluorescence (green fluorescence has higher detection sensitivity) with a maximum excitation wavelength (λ_ex) and a maximum emission wavelength (λ_em) of 470 nm and 560 nm, respectively^[8].
Note:
Doxorubicin hydrochloride is suitable for neutral or weakly acidic solvents; PBS (PH 7.4) is not recommended for dissolution, which may affect the dissolution effect.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:	Breast cancer cell lines MCF-10F, MCF-7 and MDA-MB-231
Concentration:	0, 1, 2, 4 and 8 μM
Incubation Time:	24 and 48 hours
Result:	IC₅₀ was 1 μM for both MCF-10F and MDA-MB-231 cell lines. IC₅₀ was 4 μM for MCF-7 cell line.

Cell Cycle Analysis^[5]

Cell Line:	Hct-116 human colon carcinoma cells
Concentration:	1 μM
Incubation Time:	3 hours and 24 hours
Result:	Both, bolus (3 h) and continuous (24 h) incubation led to a significant reduction of cells in G0/G1 and accumulation in G2 phase.

Western Blot Analysis^[4]

Cell Line:	Breast cancer cell lines MCF-10F, MCF-7 and MDA-MB-231
Concentration:	1 μM for MCF-10F and MDA-MB-231 cells, 4 μM for MCF-7 cells
Incubation Time:	48 hours
Result:	Bax protein expression was upregulated in MCF-10F and MDA-MB-231 cell lines but MCF-7 cells did not show any significant increase. Caspase-8 gene expression was upregulated in MCF-10F, but it was downregulated in MCF-7 and MDA-MB-231 cells.

In Vivo

Doxorubicin hydrochloride can be used to induce models of cardiotoxicity and heart failure.

1. Inducing cardiotoxicity^[10]^[11]

Background

The mechanism of short-term induction of cardiotoxicity: promoting extracellular remodeling of myocardium to induce heart failure, and also works at the molecular level. Including: interacting with iron, changing the activity of oxidases in cells or mitochondria, and binding to topoisomerases.

Specific Mmodeling Methods

Mice: Female C57BL/6j mice • 20-22 g • 6 weeks old
Administration: 2 mg/kg, 10 mg/kg • ip • once every the other day for 2 or 3 times

Note

Mice were sacrificed 3 days after the first injection.

Modeling Indicators

molecular level: (1) Pro-inflammatory cytokines (such as TNF-α and IL-6) increase significantly, while anti-inflammatory cytokine IL-10 decreases; (2) Inducible - Nitric oxide synthase (iNOS) was overexpressed and serum nitrite levels were elevated; nitrotyrosine expression was significantly increased.

Correlated Product(s): /

Opposite Product(s): /

2. Induction of heart failure^[11]^[12]

Background

The long-term mechanisms inducing heart failure remain to be carefully elucidated.

Specific Mmodeling Methods

Rat: Male Wistar rats • 180-200 g
Administration: 2.5 mg/kg • ip • once every week, for 6 weeks • treated at 4 weeks later.

Note

Modeling Indicators

Cellular/tissue level: Myocardial sarcomeres are destroyed, mitochondria are swollen and damaged, Myocardial cells showed inflammation and apoptosis (transmission electron microscopy results); myocardial fibrosis, and left ventricular collagen I and II levels were downregulated (immunohistochemistry results).
Changes in macroscopic indicators: Hemodynamic parameters and echocardiography show cardiac insufficiency and impaired left ventricular function; such as increases in LVIDd, LVIDs and LVEDP.

Correlated Product(s): /

Opposite Product(s): Captopril (HY-B0368)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female MF1 nu/nu mice bearing MDA-G8 breast tumor xenograft (6-week-old)^[6]
Dosage:	Doxorubicin (2 mg/kg); Zoledronic acid (100 μg/kg)
Administration:	Intravenous injection; once a week; 6 weeks
Result:	Moderate inhibition of subcutaneous tumor growth in mice that were treated with 2 mg/kg Doxorubicin alone or with 100 μg/kg Zoledronic acid alone compared to the saline control. Mice treated with Zoledronic acid and Doxorubicin together had statistically significant smaller mean tumor volumes on day 42 than those treated with Doxorubicin alone.

Animal Model:	Male Sprague-Dawley rats^[7]
Dosage:	1%, 2%, 4%, 5%, 6%, 10%, 20%
Administration:	Intrastriatal injection; Single dose
Result:	In doses of 4, 5, 6, 10 or 20% caused obvious loss of ipsilateral SNc and VTA neuronsz and doses of 1 or 2% failed to produce obvious neuron loss.

Clinical Trial

Molecular Weight

579.98

Formula

C₂₇H₃₀ClNO₁₁

CAS No.

25316-40-9

Appearance

Solid

Color

Red to orange

SMILES

COC1=C2C(C(C(C(O)=C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@@]4([H])C[C@H](N)[C@H](O)[C@H](C)O4)C3=C5O)=C5C2=O)=O)=CC=C1.[H]Cl

Structure Classification

Initial Source

Microorganisms

Streptomyces peucetius var. Caesius

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

H₂O : 50 mg/mL (86.21 mM; ultrasonic and warming and heat to 60°C)

DMSO : 25 mg/mL (43.10 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7242 mL	8.6210 mL	17.2420 mL
5 mM	0.3448 mL	1.7242 mL	3.4484 mL
10 mM	0.1724 mL	0.8621 mL	1.7242 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.75 mg/mL (4.74 mM); Clear solution
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Saline
Solubility: 8.33 mg/mL (14.36 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.90%

Select Batch:

Data Sheet (297 KB) SDS (557 KB)

COA (258 KB) HNMR (287 KB) RP-HPLC (244 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. John L. Nitiss, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50. [Content Brief]

[2]. Hee-KyungRhee,et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8. [Content Brief]

[3]. P D Foglesong, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-5. [Content Brief]

[4]. Nesstor Pilco-Ferreto, et al. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 2016 Aug;49(2):753-62. [Content Brief]

[5]. Regine Lüpertz, et al. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology. 2010 May 27;271(3):115-21. [Content Brief]

[6]. Penelope D Ottewell, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. [Content Brief]

[7]. Koda LY, Van der Kooy D. Doxorubicin: a fluorescent neurotoxin retrogradely transported in the central nervous system. Neurosci Lett. 1983 Mar 28;36(1):1-8. doi: 10.1016/0304-3940(83)90476-7. PMID: 6190113. 9 [Content Brief]

[8]. Kauffman MK, Kauffman ME, Zhu H, Jia Z, Li YR. Fluorescence-Based Assays for Measuring Doxorubicin in Biological Systems. React Oxyg Species (Apex). 2016;2(6):432-439. doi: 10.20455/ros.2016.873. PMID: 29707647; PMCID: PMC5921830. [Content Brief]

[9]. Mirza A Z, Shamshad H. Preparation and characterization of doxorubicin functionalized gold nanoparticles[J]. European journal of medicinal chemistry, 2011, 46(5): 1857-1860.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	1.7242 mL	8.6210 mL	17.2420 mL	43.1049 mL
	5 mM	0.3448 mL	1.7242 mL	3.4484 mL	8.6210 mL
	10 mM	0.1724 mL	0.8621 mL	1.7242 mL	4.3105 mL
	15 mM	0.1149 mL	0.5747 mL	1.1495 mL	2.8737 mL
	20 mM	0.0862 mL	0.4310 mL	0.8621 mL	2.1552 mL
	25 mM	0.0690 mL	0.3448 mL	0.6897 mL	1.7242 mL
	30 mM	0.0575 mL	0.2874 mL	0.5747 mL	1.4368 mL
	40 mM	0.0431 mL	0.2155 mL	0.4310 mL	1.0776 mL
H₂O	50 mM	0.0345 mL	0.1724 mL	0.3448 mL	0.8621 mL
	60 mM	0.0287 mL	0.1437 mL	0.2874 mL	0.7184 mL
	80 mM	0.0216 mL	0.1078 mL	0.2155 mL	0.5388 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Doxorubicin hydrochloride Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Doxorubicin hydrochloride (Synonyms: Hydroxydaunorubicin hydrochloride; ADR)

Customer Review

Other Forms of Doxorubicin hydrochloride:

430 Publications Citing Use of MCE Doxorubicin hydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All ADC Cytotoxin Isoform Specific Products:

View All AMPK Isoform Specific Products:

View All HIV Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Doxorubicin hydrochloride Related Classifications

Keywords:

Your Recently Viewed Products:

Doxorubicin hydrochloride (Synonyms: Hydroxydaunorubicin hydrochloride; ADR)

Customer Review

Other Forms of Doxorubicin hydrochloride:

Doxorubicin hydrochloride Related Antibodies

430 Publications Citing Use of MCE Doxorubicin hydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All ADC Cytotoxin Isoform Specific Products:

View All AMPK Isoform Specific Products:

View All HIV Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Doxorubicin hydrochloride Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Doxorubicin hydrochloride Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report